Document:

EX-10.52

 Exhibit 10.52 

Confidential 
 [*] Certain information in
this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. 

SETTLEMENT, RELEASE AND TERMINATION AGREEMENT 

THIS SETTLEMENT, RELEASE AND TERMINATION AGREEMENT (this “Agreement”) is dated as of April 5, 2019, and entered into by
and among Histogen Inc., a Delaware corporation (“Histogen”), PUR Biologics, LLC, a California limited liability company (“PUR”), Wylde, LLC, a Nevada limited liability company (“Wylde”),
Christopher Wiggins, an individual (“Wiggins” and together with Wylde, the “Wiggins Parties”), and Ryan Fernan, an individual (“Fernan” together with Wiggins, Wylde and PUR and their respective
Affiliated Persons, the “PUR Parties” and each is a “PUR Party”), with reference to the statements and facts set forth under “Recitals” below. Histogen, PUR, Wiggins, Wylde and Fernan are hereinafter
referred to collectively as the “Parties” and each of them is a “Party.” Capitalized terms used in this Agreement but not defined herein shall have the meanings ascribed to them in
Section 1 hereof. 
 RECITALS 

WHEREAS, Histogen and PUR are currently parties to that certain License Agreement, dated as of March 8, 2013 (the “License
Agreement”), pursuant to which Histogen granted PUR an exclusive, royalty-free, fee-free license to the Licensed Intellectual Property in the Field of Use in the Territory, and the right to exploit
the Licensed Technology throughout the Territory in the Field of Use; 
 WHEREAS, Histogen and PUR are parties to that certain Supply
Agreement, dated as of March 8, 2013 (the “Supply Agreement”), pursuant to which Histogen manufactures and supplies certain items to PUR in accordance with the provisions of the Supply Agreement; 

WHEREAS, Histogen is a member of PUR and a party to that certain Operating Agreement, dated as of March 8, 2013 (the “Operating
Agreement”); and 
 WHEREAS, the Parties, among other things, desire to terminate the License Agreement and Supply Agreement and to
settle and discharge any and all Claims they may have against one other in connection with their activities under the License Agreement, Supply Agreement and Operating Agreement, subject to the terms and conditions of this Agreement. 

NOW, THEREFORE, in consideration of the mutual covenants contained herein and for other good and valuable consideration, the receipt of which
is hereby acknowledged by each Party, each Party hereby agrees as follows: 
 1. Definitions. Defined terms used herein but not
otherwise defined shall have the meanings set forth below: 
 (a) “Affiliated Persons” means, with respect to any Party,
such Party’s affiliates, directors, officers, members, economic interest holders, managers, partners, shareholders, attorneys, advisors, agents and representatives, as applicable. 

 

 Confidential 

 

 (b) “Bulk CCM and ECM” has the meaning set forth in the Supply Agreement.

 (c) “CCM” has the meaning set forth in the Supply Agreement 

(d) “Claims” has the meaning set forth in Section 4(a). 

(e) “Company Sale” means the occurrence of any of the following in one transaction or a series of related transactions:
(i) the sale, exchange or other disposition for economic value of all or substantially all of the assets of Histogen; (ii) a merger, reorganization or consolidation for economic value in which Histogen is not the surviving entity or in
which any person or entity other than a stockholder acquires equity constituting greater than fifty percent (50%) of the outstanding equity of Histogen; or (iii) the issuance, sale or other transfer for economic value to any non-stockholder of equity constituting greater than fifty percent (50%) of the outstanding equity of Histogen. 

(f) “Confidential Information” means with respect to any Party, collectively, (i) any and all material non-public information of such Party, including, without limitation, technical data, trade secrets, know-how, research, product or service ideas or plans, software codes and
designs, algorithms, developments, inventions, patent applications, laboratory notebooks, processes, formulas, techniques, biological materials, mask works, engineering designs and drawings, hardware configuration information, agreements with third
parties, lists of, or information relating to, employees and consultants of such Party, lists of, or information relating to, suppliers and customers, price lists, pricing methodologies, cost data, market share data, marketing plans, licenses,
contract information, business plans, financial forecasts, historical financial data, budgets or other business information of such Party disclosed by such Party to any other Party, either directly or indirectly, whether in writing, electronically,
orally, or by observation; (ii) the terms, conditions, substance and contents of this Agreement; and (iii) the substance and contents of any negotiations, discussions, communications or correspondence among the Parties and/or their
respective Affiliated Persons with respect to any matter relating to this Agreement. For avoidance of doubt, with respect to any Histogen Releasee, “Confidential Information” shall also mean any and all Data and any documents, instruments
or agreements relating to or entered into in connection with the generation, study, examination or evaluation of such Data; any negotiations, discussions, meetings (including the existence, location, date, participants, agenda, content or substance
or detail of the discussions thereof) with any potential or actual financiers, vendors, customers, personnel, partners, bankers, co-venturers or any other person or entity relating to or in connection with the development, commercialization, sale,
licensing, charitable or philanthropic of any Histogen Asset; or any communications (including, without limitation, any written or oral or electronic communication), goals, objectives, strategy, plans regarding any of the foregoing. 

(g) “Controlled” has the meaning set forth in the License Agreement. 

(h) “Development Assets” those products, applications or treatments developed through use of Histogen Assets to address the
indications solely in the Field of Use. 
 (i) “ECM” has the meaning set forth in the Supply Agreement. 

  
 -2- 

 Confidential 

 

 (j) “Field of Use” means surgical applications and products in the
orthopedic, neurosurgical, acute care, surgical, and dental market place – inclusive of treatment, healing, growth, and formation technologies of bone, spine, spinal disc, cartilage structures, ligament, tendon; and, regenerative medical device
coatings. 
 (k) “Finished Product” has the meaning set forth in the Supply Agreement. 

(l) “GAAP” means generally accepted accounting principles for financial reporting in the United States, applied on a
consistent basis. 
 (m) “Histogen Assets” has the meaning set forth in Section 8(a). 

(n) “Histogen Improvements” has the meaning set forth in the License Agreement. 

(o) “Histogen LLC Interests” has the meaning set forth in Section 9. 

(p) “Intellectual Property Rights” means any and all patent rights, copyright rights, trade secret rights, sui generis
database rights, and all other intellectual and industrial property rights of any sort throughout the world (including, but not limited to, any application therefor) whether now known or hereafter existing. 

(q) “Joint Improvements” has the meaning set forth in the License Agreement. 

(r) “Joint Patents” has the meaning set forth in the License Agreement. 

(s) “Licensed Intellectual Property” has the meaning set forth in the License Agreement. 

(t) “Licensed Technology” has the meaning set forth in the License Agreement. 

(u) “Materials” has the meaning set forth in the Supply Agreement. 

(v) “Patent Rights” has the meaning set forth in the License Agreement. 

(w) “PUR Biologics LLC Improvements” has the meaning set forth in the License Agreement. 

(x) “PUR Granted Interests” means any and all interests of any type or kind including, without limitation, any license,
sublicense, covenant not to sue, pledge, mortgage or security interest or Intellectual Property Rights in, to or concerning any Histogen Asset. A complete list of all PUR Granted Interests are provided on the attached Schedule I and each person and
entity listed thereon as a holder of such interest is a “PUR Granted Interest Holder.” 

  
 -3- 

 Confidential 

 

 (y) “PUR Technical Information” means (i) any technical, scientific and
other data, information and know-how (including, but not limited to, any biological, chemical, pharmacological, toxicological, pharmaceutical, physical, analytical,
pre-clinical, clinical, safety, manufacturing and quality control data and information, and further including, but not limited to, study designs and protocols, assays and biological methodology) that
(A) is encompassed by, or developed through the use of any Histogen Asset; or (B) was or is used, created or developed either by or on behalf of PUR and relates directly to any Histogen Asset; and (ii) any and all Intellectual
Property Rights embodied in or associated with any of the foregoing. 
 (z) “Regulatory Authority” has the meaning set forth
in the License Agreement. 
 (aa) “Regulatory Filings and Approvals” has the meaning set forth in the License Agreement.

 (bb) “Releasee” means any Histogen Releasee or PUR Releasee. 

(cc) “Retained Assets” means those assets and properties other than the Histogen Assets. For avoidance of doubt, the Parties
acknowledge and agree that Histogen shall have no right, title or interest in any Retained Asset. 
 (dd) “Series D Preferred
Stock” means shares of Histogen’s Series D Preferred Stock. 
 (ee) “Technical Information” has the meaning
set forth in the License Agreement. 
 (ff) “Territory” has the meaning set forth in the License Agreement. 

(gg) “Term” has the meaning set forth in the License Agreement. 

(hh) “Transaction Agreements” mean, collectively, the License Agreement and Supply Agreement; and each is a “Transaction
Agreement.” 
 (ii) “Surviving Claims” means, collectively, Claims arising under, out of or in connection with
Article 13 of the License Agreement or Section 12.1 of the Supply Agreement, which sections are deemed to survive the termination of such agreements as respectively provided in Sections 1 and 2 below.

 2. Termination of License Agreement. The Parties mutually acknowledge and agree that the License Agreement is hereby terminated and
of no further force or effect, effective as of the date hereof. The Parties mutually acknowledge and agree that, effective as of the date hereof, all obligations, duties, fees or monies owed by a Party to any other Party under the License Agreement
are deemed satisfied and discharged in all respects, and no Party shall owe to any other Party any obligations, duties, fees or monies thereunder, except as expressly set forth in Article 13 of the License Agreement; provided,
however, that those defined terms from the License Agreement incorporated herein shall survive for purposes of interpreting such terms herein. As part of this termination, no later than the date hereof, PUR shall have sent out to each PUR
Granted Interest Holder written notices of termination of the applicable PUR Granted Interest (and delivered evidence of the same to Histogen no later than the date hereof), which each such notice shall provide for the automatic termination of such
PUR Granted Interest within thirty (30) days of the date of the applicable notice. In connection with such termination, PUR represents and warrants to Histogen that all such PUR Granted Interests are terminable upon thirty (30) days’
prior written notice thereof. 

  
 -4- 

 Confidential 

 

 3. Termination of Supply Agreement. The Parties mutually acknowledge and agree that
the Supply Agreement is hereby terminated and of no further force or effect, effective as of the date hereof. The Parties mutually acknowledge and agree that, effective as of the date hereof, all obligations, duties, fees or monies owed by a Party
to any other Party under the Supply Agreement are deemed satisfied and discharged in all respects, and no Party shall owe to any other Party any obligations, duties, fees or monies thereunder, except as expressly set forth in
Section 12.1 of the Supply Agreement; provided, however, that those defined terms from the Supply Agreement incorporated herein shall survive for purposes of interpreting such terms herein. 

4. Histogen-PUR Releases. 

(a) To the extent permitted by applicable law, Histogen, on behalf of itself and its Affiliated Persons, successors and assigns (collectively
with Histogen, “Histogen Releasors”) hereby releases, waives, and forever discharges PUR and its Affiliated Persons, successors and assigns (including those persons set forth on Schedule V attached hereto, collectively, “PUR
Releasees”) of and from any and all actions, proceedings, causes of action, suits, losses, liabilities, rights, debts, dues, sums of money, accounts, reckonings, obligations, costs, expenses, liens, covenants, contracts, controversies,
agreements, promises, damages, judgments, claims, and demands, of every kind and nature whatsoever, whether now known or unknown, foreseen or unforeseen, matured or unmatured, suspected or unsuspected, in law or equity (collectively,
“Claims”), which any Histogen Releasor ever had, now has, or hereafter can, shall, or may have against any PUR Releasee for, upon, or by reason of any matter, cause, or thing whatsoever from the beginning of time through the date of
this Agreement in connection with, arising out of, based upon or relating to any matter whatsoever, including, without limitation, the following: (i) the License Agreement; (ii) the Supply Agreement; (iii) the joint venture and
business activities of the Parties under the Transaction Agreements and Operating Agreement; or (iv) the Operating Agreement, the Histogen LLC Interests or Histogen’s ownership thereof, any economic interests, profits interests or other
equity of PUR (including, without limitation, Claims arising out of PUR’s offer and sale of economic interests pursuant to that certain Subscription Agreement dated as of October 10, 2016 or any other offer and sale of membership or
economic interests of PUR prior to the date hereof), or Histogen’s status as a member or other equity holder of PUR (but expressly excluding any Claims any Histogen Releasor may have against any PUR Releasee under the Operating Agreement,
statutory or common law or otherwise with respect to any non-Affiliated Person third party indemnification claims). The Claims released, waived and discharged pursuant to this
Section 4(a) are referred to hereinafter as the “Histogen Released Claims.” 
 (b) To the extent
permitted by applicable law, PUR, on behalf of itself and its Affiliated Persons, successors and assigns (collectively with PUR, “PUR Releasors”) hereby releases, waives, and forever discharges Histogen and its Affiliated Persons,
Dr. Gail Naughton and her Affiliated Persons and their respective successors and assigns (collectively, “Histogen Releasees”) of and from any and all Claims which any PUR Releasor ever had, now has, or hereafter can, shall, or
may have against any Histogen Releasee for, upon, or by reason of any matter, cause, or thing whatsoever from the beginning of time through the date of this Agreement in connection with, arising out of, based upon or relating to any matter
whatsoever, including, 

  
 -5- 

 Confidential 

 

 
without limitation, the following: (i) the License Agreement; (ii) the Supply Agreement; (iii) the joint venture and business activities of the Parties under the Transaction
Agreements and Operating Agreement; (iv) the Operating Agreement, the Histogen LLC Interests or Histogen’s ownership thereof, any other economic interests, profits interests or other equity of PUR (including, without limitation, Claims
arising out of PUR’s offer and sale of economic interests pursuant to that certain Subscription Agreement dated as of October 10, 2016 or any other offer and sale of membership or economic interests of PUR prior to the date hereof), or
Histogen’s status as a member or other equity holder of PUR (including, without limitation, for purposes of this release any Claims any PUR Releasor may have against any Histogen Releasee under the Operating Agreement, statutory or common law
or otherwise with respect to any third party indemnification claims); (v) any and all property or bodily injuries suffered by any PUR Party at any time for any reason; or (vi) any PUR Party’s purchase and ownership of any Histogen equity,
or the offer or sale of any Histogen equity to such persons, or any conversations, communications, correspondence, documents or instruments shared between Histogen and such persons, or any damage, loss, expense or cost suffered by any PUR Party, in
connection with or arising out of any PUR Party’s investment (including, without limitation, securities fraud Claims). The Claims released, waived and discharged pursuant to this Section 4(b) are referred to
hereinafter as the “PUR Released Claims.” 
 (c) (i) Histogen represents and warrants that neither it nor any other Histogen
Releasor has heretofore assigned or otherwise transferred or subrogated, or purported to assign, transfer or subrogate, to any person or entity, any Histogen Released Claim or interest therein or portion thereof, it, he or she may have against the
PUR Releasees. Histogen shall indemnify, defend and hold harmless the PUR Releasees from and against any and all liabilities, losses, costs and expenses (including attorneys’ fees) incurred by any PUR Releasee as the result of any person or
entity asserting any such right, assignment, transfer or subrogation; and (ii) PUR represents and warrants that neither it nor any other PUR Releasor has heretofore assigned or otherwise transferred or subrogated, or purported to assign,
transfer or subrogate, to any person or entity, any PUR Released Claim or interest therein or portion thereof, or it, he or she may have against the Histogen Releasees. PUR shall indemnify, defend and hold harmless the Histogen Releasees from and
against any and all liabilities, losses, costs and expenses (including attorneys’ fees) incurred by any Histogen Releasee as the result of any person or entity asserting any such right, assignment, transfer or subrogation. 

5. Wiggins Parties Release. 

(a) To the extent permitted by applicable law, each Wiggins Party, on behalf of himself and itself and his and its Affiliated Persons,
successors and assigns (collectively including the Wiggins Parties, “Wiggins Releasors”), hereby releases, waives, and forever discharges Histogen and each other Histogen Releasee of and from any and all Claims which any Wiggins
Releasor ever had, now has, or hereafter can, shall, or may have against any Histogen Releasee for, upon, or by reason of any matter, cause, or thing whatsoever from the beginning of time through the date of this Agreement in connection with,
arising out of, based upon or relating to any matter whatsoever, including, without limitation, the following: (i) the License Agreement; (ii) the Supply Agreement; (iii) the joint venture and business activities of the Parties under
the Transaction Agreements and Operating Agreement; (iv) the Operating Agreement, the Histogen LLC Interests or Histogen’s ownership thereof, any other economic interests, profits interests or

  
 -6- 

 Confidential 

 

 
other equity of PUR (including, without limitation, Claims arising out of PUR’s offer and sale of economic interests pursuant to that certain Subscription Agreement dated as of
October 10, 2016 or any other offer and sale of membership or economic interests of PUR prior to the date hereof), or Histogen’s status as a member or other equity holder of PUR (including, without limitation, for purposes of this release
any Claims any Wiggins Releasor may have against any Histogen Releasee under the Operating Agreement, statutory or common law or otherwise with respect to any third party indemnification claims); (v) any and all property or bodily injuries suffered
by any PUR Party at any time for any reason; or (vi) any PUR Party’s purchase and ownership of any Histogen equity, or the offer or sale of any Histogen equity to such persons, or any conversations, communications, correspondence,
documents or instruments shared between Histogen and such persons, or any damage, loss, expense or cost suffered by any PUR Party, in connection with or arising out of any PUR Party’s investment (including, without limitation, securities fraud
Claims). The Claims released, waived and discharged pursuant to this Section 5(a) are referred to hereinafter as the “Wiggins Released Claims.” 

(b) Each Wiggins Party represents and warrants that neither he, it nor any other Wiggins Releasor has heretofore assigned or otherwise
transferred or subrogated, or purported to assign, transfer or subrogate, to any person or entity, any Wiggins Released Claim or portion thereof, or interest therein it, he, she or it may have against the Histogen Releasees. Each Wiggins Party shall
indemnify, defend and hold harmless the Histogen Releasees from and against any and all liabilities, losses, costs and expenses (including attorneys’ fees) incurred by any Histogen Releasee as the result of any person or entity asserting any
such right, assignment, transfer or subrogation. 
 6. Fernan Release. 

(a) To the extent permitted by applicable law, Fernan, on behalf of himself and his Affiliated Persons, successors and assigns (collectively
with Fernan, “Fernan Releasors”), hereby releases, waives, and forever discharges Histogen and each other Histogen Releasee of and from any and all Claims which any Fernan Releasor ever had, now has, or hereafter can, shall, or may
have against any Histogen Releasee for, upon, or by reason of any matter, cause, or thing whatsoever from the beginning of time through the date of this Agreement in connection with, arising out of, based upon or relating to any matter whatsoever,
including, without limitation, the following: (i) the License Agreement; (ii) the Supply Agreement; (iii) the joint venture and business activities of the Parties under the Transaction Agreements and Operating Agreement; (iv) the
Operating Agreement, the Histogen LLC Interests or Histogen’s ownership thereof, any other economic interests, profits interests or other equity of PUR (including, without limitation, Claims arising out of PUR’s offer and sale of economic
interests pursuant to that certain Subscription Agreement dated as of October 10, 2016 or any other offer and sale of membership or economic interests of PUR prior to the date hereof), or Histogen’s status as a member or other equity
holder of PUR (including, without limitation, for purposes of this release any Claims any Fernan Releasor may have against any Histogen Releasee under the Operating Agreement, statutory or common law or otherwise with respect to any third party
indemnification claims); (v) any and all property or bodily injuries suffered by any PUR Party at any time for any reason; or (vi) any PUR Party’s purchase and ownership of any Histogen equity, or the offer or sale of any Histogen equity
to such persons, or any conversations, communications, correspondence, documents or instruments shared between Histogen and such persons, or any damage, loss, expense or cost suffered by any PUR Party, in connection with or arising out of any PUR
Party’s investment (including, without limitation, securities fraud Claims). The Claims released, waived and discharged pursuant to this Section 6(a) are referred to hereinafter as the “Fernan Released
Claims.” 

  
 -7- 

 Confidential 

 

 (b) Fernan represents and warrants that neither he nor any other Fernan Releasor has
heretofore assigned or otherwise transferred or subrogated, or purported to assign, transfer or subrogate, to any person or entity, any Fernan Released Claim or portion thereof, or interest therein it, he, she or it may have against the Histogen
Releasees. Fernan shall indemnify, defend and hold harmless the Histogen Releasees from and against any and all liabilities, losses, costs and expenses (including attorneys’ fees) incurred by any Histogen Releasee as the result of any person or
entity asserting any such right, assignment, transfer or subrogation. 
 7. Section 1542. Each of the Parties understands that he or
it may later discover Claims or facts that may be different from, or in addition to, those that he or it or any other Party now knows or believes to exist regarding the subject matter of the releases contained in Sections 4(a), 4(b),
5(a), and 6(a), and which, if known at the time of signing this Agreement, would have materially affected such Party’s decision to enter into this Agreement and grant the releases contained Sections 4(a), 4(b),
5(a), and 6(a). Nevertheless, each Party hereunder intends to fully, finally, and forever settle and release all Claims that now exist, may exist, or previously existed, as set out in the releases contained in Sections 4(a),
4(b), 5(a), and 6(a), whether known or unknown, foreseen or unforeseen, or suspected or unsuspected, and each release given herein is and will remain in effect as a complete release, notwithstanding the discovery or existence of
such additional or different facts. Each Party expressly waives any and all rights and benefits of any statutory provision or common law rule that provides, in sum or substance, that a release does not extend to claims which such Party does not know
or suspect to exist in his or its favor at the time of executing the release, which if known by him or it, would have materially affected such Party’s decision to enter into this Agreement. In particular but without limitation, each of
Histogen, PUR, Wiggins, Wylde and Fernan expressly waives the provisions of California Civil Code Section 1542, which statute provides: 

“A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS THAT THE CREDITOR OR RELEASING PARTY DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR
AT THE TIME OF EXECUTING THE RELEASE AND THAT, IF KNOWN BY HIM OR HER, WOULD HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR OR RELEASED PARTY.” 

8. Quitclaims and Irrevocable Power of Attorney. 

(a) Each PUR Party hereby waives and irrevocably relinquishes and quitclaims to Histogen any and all title, right, interest or any Intellectual
Property Rights any of them has or may have in any of the (i) Patent Rights; (ii) Technical Information (including PUR Technical Information); (iii) Histogen Improvements; (iv) Licensed Technology; (v) Licensed Intellectual
Property; (vi) Joint Improvements; (vii) Joint Patents; (viii) Finished Product; (ix) Development Assets; (x) PUR Biologics LLC Improvements encompassed by, or developed through the use of any of the rights, properties and
assets described in foregoing Sections 8(a)(i)-(ix) and Sections  

  
 -8- 

 Confidential 

 

 
8(a)(xi)-(xiii) (the “Histogen Asset PBL Improvements”); (xi) any and all Regulatory Filings relating to any of the rights, properties and assets described in foregoing
Sections 8(a)(i)-(x) and Sections 8(a)(xii)-(xiii), and Approvals obtained in connection with Parties activities under the Transaction Agreements; (xii) Data and all other data generated by or on behalf of PUR in connection with
the development or marketing of any of the foregoing in (i)-(xi); or (xiii) any other property or rights of Histogen licensed, granted or otherwise made available to any of them pursuant to the terms of any Transaction Agreement (foregoing
(i)-(xiii), the “Histogen Assets”). Each PUR Party hereby acknowledges and agrees that it or he does not have or own any right, title, interest or Intellectual Property Rights in any Histogen Asset. If, notwithstanding this
Section 8(a), after the date hereof any PUR Party retains such right or interest in any Histogen Asset, each agrees to hold the same in trust for the sole benefit of Histogen, and shall assign to Histogen all of its or his
right, title, interest and Intellectual Property Rights throughout the world in and to any such retained interest in the any such Histogen Asset, and do such other acts and deeds as may be necessary and reasonably requested by Histogen to vest any
such retained interest in Histogen (including without limitation, executing any copyright, Patent or other intellectual property assignment instrument) and/or to act on behalf of PUR with regard to any Histogen Asset. In connection with the
foregoing, each PUR Party irrevocably designates and appoints Histogen and its duly authorized officers and agents as its agent and attorney-in-fact, to act for and in
its behalf and stead to execute and file any such instruments and papers and to do all other lawfully permitted acts to vest in Histogen all of such PUR Party’s right, title, interest and Intellectual Property Rights throughout the world in and
to any Histogen Asset. This power of attorney is coupled with an interest. Each PUR Party shall execute and concurrently deliver to Histogen as part of the execution of this Agreement Exhibit A hereto confirming this Assignment and Irrevocable Power
of Attorney. 
 (b) Each PUR Party represents to Histogen that he or it has, has delivered to Histogen any and all Histogen Assets in his or
its possession, including, without limitation any Bulk CCM and ECM or Materials in their possession. 
 (c) Each PUR Party shall deliver to
Histogen a copy of all documents, data and information of any kind related to the Histogen Assets held by each PUR Party, in an electronic format accessible and usable by Histogen. Histogen shall advise the PUR Parties of any particular format in
which it requests any such documentation be provided. 
 (d) Histogen hereby waives and irrevocably relinquishes and quitclaims to PUR any
and all title, right, interest or any Intellectual Property Rights it has or may have in the tradename and/or trademark “PUR.” Histogen hereby acknowledges and agrees that it does not have or own any right, title, interest or Intellectual
Property Rights in the tradename and/or trademark “PUR.” If, notwithstanding this Section 8(a), after the date hereof any such rights or any interest therein retain, remain or continue to vest in Histogen,
Histogen agrees to hold the same in trust for the sole benefit of PUR, and shall assign to PUR all of its right, title, interest and Intellectual Property Rights throughout the world in and to any such retained or vested interest. 

  
 -9- 

 Confidential 

 

 9. Relinquishment of Histogen LLC Interests. Immediately prior to the effectiveness of
this Agreement, Histogen was a member of PUR owning membership interests representing in the aggregate forty-two percent (42%) of the outstanding equity of PUR (such membership interests, the “Histogen
LLC Interests”). In connection with the transactions contemplated hereby, and effective as of the date hereof, Histogen hereby relinquishes and quitclaims any and all right, title and interest in and to the Histogen LLC Interests such that
from and after the effectiveness of this Agreement, Histogen shall have no further right, title or interest in the Histogen LLC Interests or other equity of PUR and shall thenceforth no longer be a member of PUR Any and all obligations owed by
Histogen to any PUR Party or any other member or economic interest holder of PUR in respect of the Histogen LLC Interests or any economic interests or other equity of PUR are hereby deemed released, waived, discharged and satisfied and Histogen
shall have no further obligations to PUR, Wiggins, Wylde, Fernan or any economic interest holder or other equity holder or PUR in respect thereof. PUR shall have no further obligation to Histogen in respect of the Histogen LLC Interests. 

10. Issuance of PUR Preferred Shares. In consideration for the mutual promises, covenants and agreements contained herein, but subject
to this Section 10, Histogen shall issue to PUR 1,166,667 shares of Histogen’s Series D Preferred Stock (the “PUR Preferred Shares”). Promptly after the date hereof but subject to this
Section 10, Histogen shall deliver to PUR a stock certificate issued in the name of PUR and evidencing the PUR Preferred Shares. In connection with and as a condition precedent to the issuance of the PUR Preferred Shares,
PUR shall execute and deliver to Histogen any and all instruments, agreements and other documents to which Histogen’s common or preferred stock or the holders thereof are subject (including, without limitation, any shareholders, voting or
similar agreement), including, without limitation, the Histogen Governance Documents (as defined below). As used herein, “Histogen Governance Documents” means, collectively, (a) that certain Amended and Restated Voting
Agreement, dated August 10, 2016, by and among Histogen and certain stockholders thereof as indicated on the signature pages thereto (as amended, modified and supplement from time to time); (b) that certain Amended and Restated Right of First
Refusal and Co-Sale Agreement, dated August 10, 2016, by and among Histogen and certain stockholders thereof as indicated on the signature pages thereto (as amended, modified and supplement from time to
time); and (c) that certain Amended and Restated Investors Rights Agreement, dated August 10, 2016, by and among Histogen and certain stockholders thereof as indicated on the signature pages thereto (as amended, modified and supplement
from time to time). 
 11. Certain Payments. Prior to or at the closing of the transactions contemplated hereby, Histogen shall make
the payments in the amounts and to those persons and entities set forth on Schedule IV hereto, it being that the aggregate of such payments shall not exceed Five Hundred Thousand Dollars ($500,000). To the extent that such aggregate payments are
less than the Five Hundred Thousand Dollars ($500,000). Histogen shall remit such balance to PUR by wire transfer of immediately available funds to a bank account designated in writing by PUR to Histogen. The Parties acknowledge and agree that all
such payments shall be credited against and applied to reduce Histogen’s obligation in respect of the Cap Amount. 
 12. Application
of PUR Indebtedness to Cap Amount. The Parties acknowledge certain indebtedness owed by PUR to Histogen, the aggregate amount of which (including all related interest fees, charges or penalties accrued or assessed thereunder) is Twenty-Two Thousand Dollars ($22,000) (the “PUR Indebtedness”). PUR and Histogen hereby agree that the PUR Indebtedness shall be credited against and applied to reduce Histogen’s obligation in
respect of the Cap Amount; accordingly, PUR shall have no further obligation to Histogen in respect of the PUR Indebtedness. 

  
 -10- 

 Confidential 

 

 13. Payment to UCSD. The Parties acknowledge that, prior to the date hereof, Histogen
has made a cash payment to [the University of California – San Diego (“UCSD”)] in the amount of $23,037.50 (the “UCSD Payment”). The Parties acknowledge and agree that the UCSD Payment shall be credited against
and applied to reduce Histogen’s obligation in respect of the Cap Amount. 
 14. Commercialization of Development Assets. 

(a) Subject to any required filings and approvals required by any Regulatory Authority, during the period commencing on the date hereof and
ending on the third cl) anniversary hereof, Histogen shall use reasonable efforts (directly or indirectly or jointly with third parties) to develop and commercialize one or more of the Development Assets in the Field of Use in the Territory. If
during such period, Histogen shall have failed to use reasonable efforts to develop and commercialize one or more of the Development Assets, PUR shall have the right described in Section 14(c) below, exercisable in
PUR’s sole discretion upon written notice to Histogen (such written notice from PUR, the “PUR Notice”); provided, however, that upon Histogen’s receipt of the PUR Notice, Histogen shall have the right and
opportunity, for a period of ninety (90) days following the date of the PUR Notice, to cure such failure and demonstrate to PUR that Histogen has engaged in reasonable efforts to develop and commercialize one or more of the Development Assets.
Histogen’s cure right under this Section 14(a) shall be exercisable by written notice to PUR within thirty (30) days of the date of the PUR Notice: The three (3)-year period plus any ninety (90)-day extension thereof as provided herein is referred to hereinafter as the “Commercialization Period.” 

The Parties acknowledge and agree that (y) the expenditure by Histogen of at least * on such development and commercialization activities
during the Commercialization Period shall constitute “reasonable efforts” on the part of Histogen; and (z) the determination of whether Histogen has met such financial threshold shall include consideration of all operational,
environmental and commercial factors, including, without limitation, any and all (i) product development costs spent by Histogen to generally improve the quality, scale and efficiency of its operations and research and development activities
(including, without limitation, costs and expenses incurred in connection with scaling up its manufacturing capacity or improving its methods of conducting clinical and non-clinical studies, or developing test
methods and analytical methods); and (ii) costs spent to identify technology limitations and/or hurdles to commercial exploitation in respect of one or more of the Development Assets and/or to conduct research and development activities in
respect of one or more of the Development Assets to determine the commercial viability thereof. Notwithstanding the foregoing, Histogen’s failure to spend at least that amount shall not be automatically considered a breach of or failure to
satisfy such obligation; it being agreed to and understood by the Parties that the determination of such breach or failure shall be based on the totality of circumstances, including an evaluation of Histogen’s
non-financial efforts and activities in discharging its “reasonable efforts” obligation hereunder. Any dispute or disagreement among the Parties concerning Histogen’s satisfaction of its
obligation hereunder shall be resolved by arbitration in accordance with Section 26 below. 

  
 -11- 

 Confidential 

 

 For clarity, the failure of any Development Asset at, during or in connection with any
clinical trial or other evaluation, examination or testing required by any Regulatory Authority in connection with Histogen’s efforts to develop and commercialize such assets shall not be deemed to be a failure of Histogen to fulfill its
obligations under this Section 14. 
 (b) Subject to Sections 14(d) and 15 below, if Histogen
successfully develops and commercializes any of the Development Assets, PUR shall be entitled to the following payments and royalties (collectively, “Commercialization Payments”): 

(i) subject to the proviso in the final paragraph of this Section 14(b), an initial cash payment of * upon the
unconditional acceptance and approval of a New Drug Application or Pre-Market Approval Application in connection with the commercialization of a Development Asset by all United States Regulatory Authorities
having jurisdiction over such subject matter; 
 (ii) subject to the proviso in the final paragraph of this
Section 14(b), a second cash payment of * upon the “first mass public sale” of a Development Asset. For purposes hereof, “first mass public sale” means from and after such time as when gross sales of the
applicable Development Asset exceed * for the first time; and 
 (iii) subject to the proviso in the final paragraph of this
Section 14(b), a * percent (*%) royalty on the “net revenues” collected by Histogen from sales of any commercialized Development Asset (and for this purpose “net revenues” shall be determined in
accordance with GAAP). Any payments due pursuant to this Section 14(b) shall be paid by Histogen to PUR within thirty (30) days following the end of each calendar quarter during the period such payments are due. 

Notwithstanding the foregoing, from and after the time Histogen has completed Commercialization Payments to PUR totaling the Cap Amount
(taking into account any other payments or other amounts credited against and applied to reduce Histogen’s obligation in respect of the Cap Amount as permitted hereunder), Histogen shall have no further obligation to make additional
Commercialization Payments or other payments to PUR and PUR shall have no further right to any such payments, whether or not Histogen successfully develops and commercializes any additional Development Assets. In addition, from and after such time,
PUR shall have no further right, interest or title in the Development Assets or in any income, revenues or other amounts generated from the sales or other exploitation of the Development Assets. For avoidance of doubt, the Cap Amount represents the
entire consideration owed by Histogen to PUR, Wiggins, Wylde or Ferran in connection with Histogen’s successful development and commercialization of any Development Asset. For purposes hereof, “Cap Amount” means *. 

(c) If it is determined that Histogen failed to use commercially reasonable efforts to develop and commercialize the Development Assets during
the Commercialization Period, PUR shall have the right and option, exercisable by written notice to Histogen within twelve (12) months of expiration of the Commercialization Period, to require Histogen to license the Development Assets to PUR
for an initial, upfront payment of * (the “Upfront Payment”) (provided, however, for clarity, in connection with such license, Histogen may require additional commercially reasonable royalty or other payments). For
avoidance of doubt, Histogen shall have 

  
 -12- 

 Confidential 

 

 
no obligation to license the Development Assets pursuant to this Section 14(c) until it has received the Upfront Payment in full. If PUR fails to exercise its option
hereunder within such twelve (12)-month period, the option shall lapse automatically without further action on the Parties and thereafter PUR shall have no further right, title or interest or option in any Histogen Assets (including, without
limitation, any Development Asset). 
 (d) PUR’s rights under Sections 14(a), (b) and (c) shall terminate
automatically and shall be of no further force or effect in the event of a sale as provided in Section 15. 
 15.
Sale. If Histogen shall sell and transfer all or substantially all the Development Assets to an unaffiliated person or entity for cash proceeds or other consideration within one (1) year of the date hereof, PUR shall be entitled to:
(a) with respect to any cash proceeds, * percent (*%) of such cash proceeds net of any transaction costs incurred by Histogen in connection with such sale (e.g., legal and accounting fees, advisors’ and finders’ fees, etc.); or
(b) with respect to any non-cash property (e.g., personal or real property, securities, etc.), a * percent (*%) undivided interest in such non-cash property and any
cash proceeds generated from the sale thereof (net of transaction costs). For avoidance of doubt, PUR’s rights under this Section 15 shall apply only to a sale of assets by Histogen involving exclusively the
Development Assets or a sale of assets of which the Development Assets constitute all or substantially all of such assets. Histogen shall have no obligation to PUR, and PUR shall have no rights, pursuant to Section 14 or
this Section 15 in the event of a Company Sale; provided, however, that the assignee or transferee in connection with such Company Sale shall assume and continue to be responsible for the obligations set forth
in Section 14. 
 16. No Admission of Liability. This Agreement constitutes a compromise, settlement, and
release of Claims and is being entered into solely to avoid the burden, inconvenience, and expense of litigating such Claims. No Party admits any liability with respect to any such Claim and the subject matter of this Agreement; any such liability
is hereby expressly denied and disclaimed. This Agreement is not to be construed or deemed an admission by any Party of liability at any time for any Claims being compromised, settled, and released or the subject matter hereof. 

17. Covenant Not to Sue; Non-Disparagement. 

(a) No Party shall encourage, induce or solicit the prosecution of, or initiate, institute, commence, continue, file, or otherwise prosecute
(directly, indirectly, individually or jointly with or through any third party) with respect to any Regulatory Authority, governmental unit or agency, court or similar tribunal, any Histogen Released Claim, PUR Released Claim, Wiggins Released Claim
or Ferran Released Claim against Histogen, PUR, any Histogen Releasees or any PUR Releasees, as applicable. No Party shall communicate with any Regulatory Authority, governmental unit or agency regarding any Confidential Information concerning the
Parties joint venture activities under the Transaction Agreements or Operating Agreement or this Agreement or any document or instrument contemplated hereby. Each Party further agrees that this Agreement is, shall constitute, and may be pleaded as a
bar to any such attempted or actual prosecution of a Histogen Released Claim, PUR Released Claim, Wiggins Released Claim or Ferran Released Claim. 

  
 -13- 

 Confidential 

 

 (b) No Party shall, and each Party shall cause its agents and representatives not to, at any
time directly or indirectly (including through one or more intermediaries) make, publish, or communicate to any person or entity or in any public forum any comment or statement, written or oral or in electronic format, that criticizes, deprecates,
denigrates or disparages, or otherwise take any action which could reasonably be expected to adversely affect, the personal, professional or business reputation of any other Party or Releasee. 

18. Representations and Warranties. 

(a) Each PUR Party represents and warrants to Histogen as follows: (i) he or it has the absolute and unrestricted right, power and
authority to execute and deliver this Agreement and any document or instrument contemplated hereby and to perform his or its obligations hereunder and thereunder, and such action has been duly authorized by all necessary action by managers,
directors and members of PUR and Wylde; (ii) neither the execution and delivery of this Agreement or any document or instrument contemplated hereby nor the consummation or performance of any of the transactions contemplated hereunder or
thereunder will, directly or indirectly (with or without notice or lapse of time) will: (A) breach any provision of any governing or organizational document of PUR or Wylde; (B) breach or give any Regulatory Authority or other person or
entity the right to challenge any of the transactions contemplated hereunder or to exercise any remedy or obtain any relief under any applicable law; (C) contravene, conflict with or result in a violation or breach of any of the terms or
requirements of, any order to which any PUR Party or any of their assets are subject; or (D) result in the imposition or creation of any lien or encumbrance upon or with respect to any of the Histogen Assets; (iii) it or he has not sold,
pledged, assigned, leased (as lessor or lessee), licensed, transferred, abandoned or otherwise disposed of any Histogen Asset or relinquished any material right related to any Histogen Asset, except as expressly permitted under the License Agreement
and Supply Agreement; (iv) this Agreement (assuming due execution and delivery by the other Parties hereto) constitutes the legal, valid, and binding obligation of such Party, enforceable against such Party in accordance with its terms, except
as may be limited by any applicable bankruptcy, insolvency, reorganization, moratorium, or similar laws and equitable principles related to or affecting creditors’ rights generally or the effect of general principles of equity; (v) there
are no Joint Patents, Joint Improvements or Histogen Asset PBL Improvements, except for the Joint Patents, Joint Improvements and Histogen Asset PBL Improvements set forth on Schedule II hereto; (vi) there are no PUR Granted Interests other
than as set forth on Schedule I; (vii) except for the PUR Granted Interests, no PUR Party has assigned, conveyed, transferred, sold or licensed to any person or entity any right, title or interest to any Histogen Asset (including, without
limitation, any Data) nor has any PUR Party granted or pledged to any person or entity any lien, security interest or encumbrance in any Histogen Asset (including, without limitation, any Data); and (viii) no PUR Party has disposed of or
transferred any Histogen Asset or Retained Asset in a manner that would constitute, and the consummation by the Parties of the transactions contemplated hereby will not constitute, a fraudulent conveyance or fraud on creditors of PUR under
applicable law. 

  
 -14- 

 Confidential 

 

 (b) Histogen represents and warrants to each PUR Party as follows: (i) it has the
absolute and unrestricted right, power and authority to execute and deliver this Agreement and any document or instrument contemplated hereby and to perform its obligations hereunder and thereunder, and such action has been duly authorized by all
necessary action by stockholders and directors of Histogen; (ii) neither the execution and delivery of this Agreement or any document or instrument contemplated hereby nor the consummation or performance of any of the transactions contemplated
hereunder or thereunder will, directly or indirectly (with or without notice or lapse of time) will: (A) breach any provision of any governing or organizational document of Histogen; (B) breach or give any Regulatory Authority or other
person or entity the right to challenge any of the transactions contemplated hereunder or to exercise any remedy or obtain any relief under any applicable law; or (C) contravene, conflict with or result in a violation or breach of any of the
terms or requirements of, any order to which Histogen or any of its assets is subject; and (iii) this Agreement (assuming due execution and delivery by the other Parties hereto) constitutes the legal, valid, and binding obligation of Histogen,
enforceable against it in accordance with its terms, except as may be limited by any applicable bankruptcy, insolvency, reorganization, moratorium, or similar laws and equitable principles related to or affecting creditors’ rights generally or
the effect of general principles of equity. 
 EXCEPT FOR THE EXPRESS REPRESENTATIONS AND WARRANTIES SET FORTH IN THIS SECTION 18, (Y) NO
PARTY NOR ANY PERSON ON SUCH PARTY’S BEHALF HAS MADE OR MAKES ANY EXPRESS OR IMPLIED REPRESENTATION OR WARRANTY WHATSOEVER, AND (Z) EACH PARTY ACKNOWLEDGES THAT, IN ENTERING INTO THIS AGREEMENT, IT OR HE HAS NOT RELIED UPON ANY
REPRESENTATION OR WARRANTY EXCEPT AS SPECIFICALLY PROVIDED IN THIS SECTION 18. 
 19. Confidentiality. Each Party acknowledges the
confidential nature of the Confidential Information. Subject to this Section 19, each Party agrees, for itself and himself and on behalf of its or his Affiliated Persons, that he or it shall (a) not, directly or
indirectly, disclose any of the Confidential Information to any person or entity, except to such Party’s Affiliated Persons who need to know the Confidential Information to assist such Party, or act on its or his behalf, to exercise its or his
rights or perform its or his obligations under this Agreement, but only if such Affiliated Persons are advised of the confidential nature of such Confidential Information and that by receiving such Confidential Information such Affiliated Persons
are agreeing to be bound by the terms of this Section 19; (b) safeguard and keep in confidence (and cause its or his Affiliated Persons to safeguard and keep in confidence) the Confidential Information in accordance with
the terms hereof with no less than a commercially reasonable degree of care; (c) not use the Confidential Information, or permit it to be accessed or used, for any purpose other than to exercise its or his rights or perform its or his
obligations under this Agreement, and shall cause its or his respective Affiliated Persons to refrain from doing the same; and (d) not publicly disclose or issue any press release, make any other public statement, or otherwise communicate with
the media, concerning the Confidential Information, and shall cause its or his Affiliated Persons to refrain from doing the same. Each Party shall be responsible for any breach of this Section 19 caused by any of its or his
Affiliated Persons. If, upon the advice of counsel, a Party is required to disclose Confidential Information pursuant to any law, regulation or legal or judicial process, prior to making any such disclosure, such Party shall provide the other
Parties prompt written notice thereof and reasonable assistance in opposing such disclosure and/or obtaining assurances from the applicable court or agency that such Confidential Information will be afforded confidential treatment in its disclosure.

  
 -15- 

 Confidential 

 

 20. Indemnification. 

(a) Histogen shall defend, indemnify and hold harmless each PUR Releasee from and against any and all losses, damages, liabilities, suits,
costs, or expenses of whatever kind, including reasonable attorneys’ fees, incurred or suffered by any PUR Releasee and resulting from or arising out of or in connection with a breach by any Histogen Releasee of its representations, warranties,
covenants or other obligations set out in this Agreement, as determined by a court or other tribunal with competent jurisdiction over the matter in a final, non-appealable judgment. 

(b) Each PUR Party shall defend, indemnify and hold harmless each Histogen Releasee from and against any and all losses, damages, liabilities,
suits, costs, or expenses of whatever kind, including reasonable attorneys’ fees, incurred or suffered by any Histogen Releasee and resulting from or arising out of or in connection with a breach by any PUR Releasee of its representations,
warranties, covenants or other obligations set out in this Agreement, as determined by a court or other tribunal with competent jurisdiction over the matter in a final, non-appealable judgment. 

(c) Fernan shall defend, indemnify and hold harmless each Histogen Releasee from and against any and all losses, damages, liabilities, suits,
claims, costs, or expenses of whatever kind, including reasonable attorneys’ fees, incurred or suffered by any Histogen Releasee resulting from or arising out of or in connection with any and all property or bodily injuries suffered by any
third party as a result of Fernan providing or supplying Histogen’s hair growth product to such third party. 
 (d) An indemnified Party
seeking indemnification under this Agreement shall provide to the indemnifying Party: (i) prompt written notice of the relevant claim setting forth in reasonable detail the nature and circumstances of the claim and the indemnified Party’s
basis for indemnification hereunder; provided, however, that failure to provide such notice shall not relieve the indemnifying Party from his, her or its liability or obligation hereunder except to the extent of any material prejudice
directly resulting from such failure; and (ii) reasonable cooperation, at the indemnifying Party’s expense, in the defense of such claim. The indemnifying Party shall have the right to control the defense and settlement of any such claim;
provided, however, that the indemnifying Party shall not, without the prior written approval of the indemnified Party, settle or dispose of any such claim without the prior consent of the indemnified Party. The indemnified Party shall
have the right to participate in the defense at its or his own expense. 
 21. Data. No later than the date hereof, the PUR Parties shall use
best efforts to deliver to Histogen (a) copies of all records and data (“Data”) generated in connection with the Parties’ activities under any Transaction Agreement and the Operating Agreement relating to the Histogen
Assets. For the avoidance of doubt, Data includes copies of any clinical or other studies, experiments and trials conducted or undertaken by the Parties in connection with their activities under the Transaction Documents and Operating Agreement
(including, without limitation, those studies, experiments and trials set forth on Schedule RI attached hereto) relating to the Histogen Assets; and (b) to the extent relating to the Histogen Assets, copies of all records and data related to
the PUR Parties’ interactions with Regulatory Authorities or any potential or actual financiers, vendors, customers, personnel, partners, bankers, co-venturers or any other person or entity arising out of, relating to or in connection with the
development, commercialization, sale, licensing, charitable or philanthropic of any Histogen Asset or the joint venture activities of the Parties pursuant to any Transaction Agreement or the Operating Agreement. Notwithstanding the foregoing, within
180 days of the date hereof, the PUR Parties shall deliver to Histogen copies of all the documents described in Section 21 hereof. 

  
 -16- 

 Confidential 

 

 22. Joint and Several Obligations. The obligations of each of PUR, Wiggins, Wylde and
Fenian under this Agreement shall be joint and several. 
 23. Notices. All notices, requests, demands, instructions and other
communications hereunder shall be in writing and shall be deemed to be effective only if delivered by hand, by e¬mail or facsimile transmission, by nationally-recognized overnight courier service or by prepaid United States registered or
certified mail, return receipt requested, to the address set forth for each Party on the signature page hereto, or such other address as such Party may specify by written notice to the other from time to time in accordance with this Agreement. Such
notices, requests, demands and other communication hereunder shall be deemed to have been given when received by the other Party or, if earlier, on the day after the date of delivery at the stated address. 

24. Further Assurances. Each of the Parties shall, and shall cause their respective Affiliated Persons to, from time to time at the
request and sole expense of the requesting Party, without any additional consideration, furnish the other Party such further information or assurances, execute and deliver such additional documents, instruments, and conveyances, and take such other
actions and do such other things, as may be reasonably necessary or desirable to carry out the provisions of this Agreement and give effect to the transactions contemplated hereby. 

25. Governing Law and Venue. This Agreement and all matters arising out of or relating to this Agreement, whether sounding in contract,
tort, or statute, are governed by, and construed in accordance with, the laws of the State of California, United States of America, without giving effect to the conflict of laws provisions thereof to the extent such principles or rules would require
or permit the application of the laws of any jurisdiction other than those of the State of California. 
 26. Arbitration. All claims,
controversies or disputes arising under or in connection with this Agreement, between or among any of the parties hereto, whether sounding in contract or tort, including arbitrability and any claim that this Agreement was induced by fraud (the
“Covered Claims”), will be resolved by binding arbitration in Orange County, California in accordance with the following terms and conditions: 

(a) The arbitration of all Covered Claims will be administered by the American Arbitration Association (“AAA”) in accordance
with the AAA Commercial Arbitration Rules then in effect, except that the arbitration proceedings will be governed by California procedural law as if the Covered Claims had been brought in a state court of California; provided,
however, that (i) the Parties waive any right to jury; (ii) there shall be no interlocutory appellate relief (such as writs) available; (iii) discovery will be limited to matters which are directly relevant to the issues in the
arbitration; and (iv) any award of the Arbitrator shall be final and binding and non-appealable. 

  
 -17- 

 Confidential 

 

 (b) The arbitration will take place in the Orange County, California and be conducted by a
single, neutral arbitrator (“Arbitrator”), to be selected as follows: (i) within seven business days from service of an arbitration complaint, the arbitrating parties will endeavor in good faith to agree upon an Arbitrator; and
(ii) failing such agreement under subparagraph (i) above, the arbitrating parties, or any arbitrating party, will ask AAA to supply the parties with a list of no less than seven (7) arbitrators having no less than five
(5) years’ experience in arbitrating complex business arrangements. Upon receipt of that list of potential arbitrators, each of the arbitrating parties will communicate within seven (7) days to AAA the names of four
(4) arbitrators from the list that such party would agree to use or its right to participate in the selection of the arbitrator will be forfeited. As soon as AAA receives the selections from affected parties, AAA will review the selected
arbitrators and appoint one of those arbitrators whose name appears on all of the lists submitted by the arbitrating parties. AAA will have the discretion to select the arbitrator that it believes is best suited for the arbitration in terms of
experience and availability, and AAA’s selection will be final. 
 (c) The Arbitrator may, in the course of the proceedings, order any
interim, provisional or emergency relief, remedy or measure (including, without limitation, attachment, preliminary injunction, or the deposit of specified security) that the Arbitrator considers to be necessary, just and equitable. The failure of
an arbitrating party to comply with such an interim order may, after due notice and opportunity to cure such noncompliance, be treated by the Arbitrator as a default, and some or all of the claims or defenses of the defaulting party may be stricken
and partial or final award entered against such party, or the Arbitrator may impose such lesser sanctions as the Arbitrator may deem appropriate. This Section will not preclude the arbitrating parties from seeking provisional remedies in aid of
arbitration from a court of appropriate jurisdiction, and each of the parties irrevocably submits to the jurisdiction of the state and federal courts located in the Orange County, California, in conjunction with an application for a provisional
remedy. 
 (d) The term “Covered Claims” as used in this Agreement does not include compulsory or permissive cross-claims
between or among the arbitrating parties that arise in a legal action brought by or against a non-signatory hereto (“Non-Signatory Action”). However, a
party that has the right to assert a permissive cross-claim against another party in a Non-Signatory Action may choose to treat that claim as a Covered Claim and assert it in accordance with the terms of this
Agreement. 
 (e) A full stenographic or electronic record of all proceedings in the arbitration will be maintained, and the Arbitrator will
issue rulings, a statement of decision and a judgment as if the Arbitrator were a sitting judge of the state court of California, with all of the powers (including with respect to remedies) vested in such a judge. The fees and costs of creating and
maintaining a stenographic or electronic record will be initially born by the parties in equal amounts, pro rata. 
 (f) A decision of the
Arbitrator will have the same force and effect with respect to collateral estoppel, res judicata and law of the case that such decision would have been entitled to if decided in a court of law, but in no event will such a decision be used by
or against a party to this Agreement in a Non-Signatory Action. 

  
 -18- 

 Confidential 

 

 (g) The Parties consent and submit to the exclusive personal jurisdiction and venue of the
state and federal courts located in Orange County, California to confirm any arbitration award granted pursuant to this Agreement, including, but not limited to, any award granting equitable relief, and to otherwise enforce this Agreement and carry
out the intentions of the Parties to resolve all Covered Claims through arbitration. This Section does not prevent the Parties from enforcing the award of the Arbitrator in the court of any other state, to the extent permitted by law (for example,
if property that is the subject of the award is located in another state). 
 (h) All arbitration proceedings will be closed to the public
and confidential, and all records relating thereto will be permanently sealed, except as necessary, and only to the extent reasonably necessary, to obtain court confirmation of the judgment of the Arbitrator, and except as necessary, and only to the
extent reasonably necessary, to give effect to res judicata and collateral estoppel (e.g., in a dispute between the parties that is not a Covered Claim), in which case all filings with any court will be sealed to the extent permitted by the court. A
Party (including such Party’s counsel or other Affiliated Persons) may disclose to the media only the fact and generic nature of a Covered Claim that is being, or has been, arbitrated pursuant to this Agreement. Nothing in this Section is
intended to, or shall, preclude a party from communicating with, or making disclosures to, its lawyers, tax advisors, auditors, lenders, investors, landlords, regulators and insurers, as necessary and appropriate or from making such other
disclosures as may be required by law. 
 (i) The Parties will share equally in the fees of the Arbitrator and the administrative costs of
the arbitration; provided, however, that the prevailing Party in the arbitration will be entitled to recover its fees and costs (including attorneys’ fees) from the other Party. 

27. Amendment and Assignment. This Agreement, and each of the terms and provisions hereof, may only be amended, modified, waived, or
supplemented by an agreement in writing signed by each Party. No PUR Party may assign its or his rights or obligations hereunder, whether by operation of law or otherwise, without the prior written consent of Histogen. Histogen may assign its rights
or obligations hereunder without the prior written consent of any PUR Party (but with notice thereof to PUR). Subject to the foregoing, this Agreement shall bind and inure to the benefit of the parties, their respective successors and permitted
assigns. 
 28. Interpretation. For Purposes of this Agreement, (a) the words “include,” “includes” and
“including” are deemed to be followed by the words “without limitation” or “but not limited to”; (b) the word “or” is not exclusive; (c) the words “herein,” “hereof,”
“hereby,” “hereto” and “hereunder” refer to this Agreement as a whole; (d) words denoting the singular have a comparable meaning when used in the plural, and vice-versa; and (e) words denoting any gender
include all genders. The Parties drafted this Agreement without regard to any presumption or rule requiring construction or interpretation against the party drafting an instrument or causing any instrument to be drafted. The headings in this
Agreement are for reference only and do not affect the interpretation of this Agreement. 
 29. Severability and Counterparts. If any
term or provision of this Agreement is invalid, illegal, or unenforceable in any jurisdiction, such invalidity, illegality, or unenforceability shall not affect any other term or provision of this Agreement or invalidate or render unenforceable such
term or provision in any other jurisdiction. This Agreement may be executed in counterparts, each of which is deemed an original, but all of which constitute one and the same agreement Delivery of an executed counterpart of this Agreement
electronically or by facsimile shall be effective as delivery of an original executed counterpart of this Agreement. 

  
 -19- 

 Confidential 

 

 30. Entire Agreement. This Agreement is the sole and entire agreement of the Parties
regarding the subject matter contained herein, and supersedes all prior and contemporaneous understandings, agreements, representations, and warranties, both written and oral, regarding such subject matter. Histogen, on the one hand, and each of the
PUR Parties, on the other hand, shall pay its or his own costs and expenses in connection with the drafting, negotiation, and execution of this Agreement (including fees and expenses of its legal counsel). 

[signature page follows] 

  
 -20- 

 Confidential 

 

 IN WITNESS WHEREOF, the undersigned have caused this Agreement to be executed as of the date
first written above. 
  

			
	HISTOGEN
		
	By:	 	 /s/ Richard W. Pascoe

	Name:	 	Richard W. Pascoe
	Title:	 	Chairman and CEO
	
	Notice Address and Email:
	
	10655 Sorrento Valley Road, Ste 200
	San Diego, CA 92121
	Attn: Director of Business Operations
	Email:
	
	PUR BIOLOGICS, LLC
		
	By:	 	 /s/ Ryan Fernan

	Name:	 	Ryan Fernan
	Title:	 	Manager
	
	Notice Address and Email:
	
	Attn: Ryan Fernan
	
	Email:

 [signature page continues] 

  
 -21- 

 Confidential 

 

 
			
	 /s/ Christopher Wiggins

	CHRISTOPHER WIGGINS, individually
	
	Notice Address and Email:
	
	Attn: Christopher Wiggins
	
	Email:
	
	 /s/ Ryan Fernan

	RYAN FERNAN, individually
	
	Notice Address and Email:
	
	Email:
	
	WYLDE, LLC
		
	By:	 	 /s/ Christopher Wiggins

	Name:	 	CHRISTOPHER WIGGINS
	Title:	 	Manager

  
 -22-EX-10.53

 Exhibit 10.53 

CONVERSION, TERMINATION AND RELEASE AGREEMENT 

THIS CONVERSION, TERMINATION AND RELEASE AGREEMENT (this “Agreement”) is made and entered into as of this 10th day of
August, 2016 (the “Effective Date”), by and among, on the one hand, Mr. Jonathan Jackson, an individual (“Jackson”), Lordship Ventures LLC, a Delaware limited liability
company (“Lordship Ventures”), and Lordship Ventures Histogen Holdings LLC, a Delaware limited liability company (“Lordship Holdings”), and on the other hand, Histogen, Inc., a Delaware
corporation (the “Company”). This Agreement refers to Lordship Ventures, Lordship Holdings, and Jackson each as a “Lordship Party” and collectively as the “Lordship Group”, and
to each of the parties named above as a “Party” and together as the “Parties”. 
 RECITALS

 A. Lordship Holdings is a stockholder of the Company and a holder of certain promissory notes, some of which are secured by the
intellectual property assets of the Company. 
 B. Lordship Holdings and Lordship Ventures are each a party to various agreements with the
Company. 
 C. The Company is in advanced stages of negotiating an Exclusive License Agreement with Pineworld Capital Limited, a Hong Kong
corporation (“Huapont”), and a financing in which Huapont is expected to purchase shares of the Company’s Series D Preferred Shares (the “Huapont Financing”) in exchange for a $6,000,000
investment in a closing to occur immediately following the execution of this Agreement (the “Closing”). 
 D. The
Parties wish to agree to the terms and conditions of this Agreement to induce Huapont to make the investment under the Huapont Financing, including to: (i) amend, terminate and clarify certain agreements among them; (ii) waive and release
claims in connection with such agreements, and (iii) identify additional conditions under which the promissory notes issued to Lordship Holdings would convert into shares of the Company’s capital stock, all as further set forth below. 

NOW, THEREFORE, in consideration of these premises and for other good and valuable consideration, the receipt and sufficiency of which
are hereby acknowledged, the Parties hereto agree as follows:  
 1. Definitions. For purposes of this Agreement, in
addition to the bold capitalized terms defined in other Sections of this Agreement and in Schedule A, the following terms shall have the meanings ascribed to them below: 

“Adjustment” has the meaning set forth in the Series C Note. 

“Affiliate” means, with respect to any Person, (a) any other Person who directly or indirectly, controls, is
controlled by or is under common control with such Person, including any general partner, limited partner, managing member, officer or director of such Person, or any venture capital fund now or hereafter existing which is controlled by one or more
general partners or managing members of, or shares the same management company with, such Person, or (b) a general or limited partner of such Person. 

“Amended and Restated Investment Documents” means the Amended and Restated Right of First Refusal Agreement, Amended
and Restated Investors Rights Agreement, and Amended and Restated Voting Agreement, each to be entered into by the Company, Lordship Holdings and Huapont in connection with the Closing in the forms attached hereto as Exhibit A. 

  
 -1- 

 “Claim” means any claim, action, cause of action, demand, lawsuit,
arbitration, inquiry, audit, notice of violation, proceeding, litigation, citation, summons, subpoena or investigation of any nature, civil, criminal, administrative, regulatory or otherwise, whether at law or in equity. 

“Deemed Liquidation” has the meaning set forth in the Amended and Restated Certificate of Incorporation of the Company
to be filed with the Secretary of State of the State of Delaware immediately prior to the Closing, and amendments thereto. 

“Effective Time” means immediately before the Closing. 

“Governmental Body” means any: (A) nation, state, county, city, town, district, or other jurisdiction of any
nature; (B) federal, state, local, municipal, foreign, or other government; (C) governmental or quasi-governmental authority of any nature (including any governmental agency, branch, department, official, or entity and any court or other
tribunal); (D) multinational organization or body; or (E) body exercising, or entitled to exercise, any administrative, executive, judicial, legislative, police, regulatory, or taxing authority or power of any nature. 

“Intellectual Property Rights” means, with respect to a Person, any and all patents, patent applications and other
patent rights and any other governmental authority-issued indicia of invention ownership, including the patents and patent applications, and all reissues, divisions, continuations,
continuations-in-part, renewals, extensions and reexaminations thereof and amendments thereto), any and all trademarks, service marks, trade names, brand names, logos,
trade dress, design rights and other similar designations of source, whether registered or unregistered, including the trademark registrations and applications, together with the goodwill connected with the use thereof and symbolized thereby and all
extensions and renewals thereof, any and all copyrights, copyright applications and registrations, and like protections in each work of authorship, whether registered or unregistered and whether published or unpublished, including the copyright
registrations and applications, and all extensions and renewals thereof, all rights of any kind whatsoever accruing under any of the foregoing provided by applicable law of any jurisdiction, by international treaties and conventions and otherwise
throughout the world, any and all licenses and other agreements in which such Person has granted or is granted a license or other right under any of the foregoing, any and all royalties, fees, income, payments and other proceeds now or hereafter due
or payable with respect to any and all of the foregoing, any and all Claims, whether occurring before, on or after the date hereof, including all rights to and claims for damages, restitution and injunctive and other legal and equitable relief for
past, present and future infringement, dilution, misappropriation, violation, misuse, breach or default, with the right but no obligation to sue for such legal and equitable relief and to collect, or otherwise recover, any such damages or Losses.

 “Lordship Agreement” means each of the agreements set forth in Schedule A, and collectively, the
“Lordship Agreements” 
 “Loss” means any liability, loss, claim, settlement payment, cost,
expense, interest, award, judgment, damages (including punitive damages), diminution in value, fines, fees, penalties or other charge, and any taxes. 

“New Maturity Date” means February 1, 2018. 

  
 -2- 

 “Previous Stockholder Rights” means, except as set forth in the
Amended and Restated Financing Documents, any rights of the Lordship Parties, obligations of the Company or restrictions on the Company that were intended to (or did) protect the Lordship Parties or its rights as a stock holder under the Previous
Stockholder Agreements, all previous Certificates of Incorporation (the Fourth Amended and Restated Certificate of Incorporation, the Third Amended and Restated Certificate of Incorporation, the Second Amended and Restated Certificate of
Incorporation, the (previous) Amended and Restated Certificate of Incorporation and the original Certificate of Incorporation) and previous Bylaws of the Company. 

“Person” means any individual, corporation, general or limited partnership, limited liability company, joint venture,
trust, association, organization, or other entity or Governmental Body. 
 “Released Parties” means Company, its
Affiliates, and each of their respective current and former officers, directors, employees, members, agents, investors, attorneys, shareholders, administrators, insurers, representatives, trustees, divisions, and subsidiaries, and predecessor and
successor Persons and assigns. 
 “Trigger Amount” means at least Seventeen Million Dollars ($17,000,000) in gross
revenue determined in accordance with general accepted accounting principles from July 1, 2016, together with funds raised by the Company on or after the Effective Date by (a) the sales of equity securities with no redemption rights (or
similar rights) to cause the Company to repurchase such shares in less than two years from issuance, or (b) the sales of assets; less the amount paid by the Company to: (i) redeem or repurchase any of its then outstanding securities
following the Effective Date; (ii) to pay any dividends or distributions to the Company’s equity holders; (iii) repay the Promissory Note issued to Leonard H. Lavin dated Oct 22, 2008; and provided further that the funds that are
designed for the purpose of artificially achieving the Trigger Amount shall not be included in the Trigger Amount; and further, that funds from sales under subsections (a) or (b) that are approved by the Board are counted to the full extent
funds are received by the Company notwithstanding that they may arise from related party transactions. To remove any doubt, the $5,750,000 raised (if raised) in the Closing will count towards the Trigger Amount. 

2. Conversion of the Series C Note. Effective as of the Effective Time, all principal amounts outstanding under the Series C Note will
convert automatically and without further action by the Parties into (i) 3,000,000 shares of the Company’s Series C Preferred, (ii) 1,672,829 shares of the Company’s Common Shares (after taking into account the Adjustment to be effectuated
upon the completion of the Huapont Financing), and (iii) the right as set forth in the Series C Note to receive the benefit of future Adjustments (the “Series C Conversion”). All interest accrued under the Series C Note
will be deemed waived. Lordship represents and warrants that neither the Lordship Group nor any of its Affiliates has any other debt instrument or debt security, convertible or otherwise, under which the Company has any other obligation to any
Lordship Party other than the Series B Notes and the 2016 Notes, except as may be contained in the Continuing Agreements. In connection with the foregoing, the Company hereby agrees to issue to Lordship Holdings such shares of capital stock, and
shall promptly issue to Lordship Holdings, stock certificates in respect of the foregoing and record such stock certificates in the Company’s stock ledger. Lordship confirms and agrees that, if the disclosure contained in Section 4.2(c) of
the Series D Stock Purchase Agreement to be entered into between Huapont and the Company in connection with the Huapont Financing (“Purchase Agreement”) is true and correct, then 1,672,829 shares of the Company’s Common
Shares will be due and to be issued to Lordship Holdings upon the Series C Conversion after taking into account the Adjustment to be effectuated upon the consummation of the Huapont Financing. 

  
 -3- 

 3. Other Debt Obligations. Effective as of the Effective Time, all of the Released
Parties obligations under all Convertible Note Documents shall be deemed satisfied, all of the outstanding principal and interest thereon shall be deemed fully paid and cancelled, and all obligations, covenants, representations or warranties under
the Convertible Note Documents together with the Convertible Note Documents themselves will be deemed terminated and of no further force or effect except: (a) the following Sections of the Third NPA: 6.1(c)-(g),(j),(k), Article
VIII and all definitions in such agreement; provided that they will not be in effect from the Effective Date to six (6) months thereafter; (b) the Series B Notes as amended by this Agreement; and (c) the provisions in the
Series C Note governing the Company’s obligation to effectuate Adjustments after the Conversion based on subsequent Securities Issuance Transactions (as defined in the Series C Note) after the Closing, including without limitation,
Section 3 thereof. For the avoidance of doubt, though the 2016 Notes are not Convertible Note Documents, they too shall remain in effect, as amended by this Agreement. At the Closing, Lordship will tender all Loan Term Sheets, Preliminary
Series B Notes, and the Common Stock Warrant for cancellation. 
 4. The Series B Notes. 

4.1 New Maturity Date. Each Series B Note is hereby amended so that the definition of “Payment Date”, as set forth in
Section 1 of each such note, is amended to be the New Maturity Date, meaning that the holder of any Series B Note may not call or otherwise demand payment of all or any portion of such Series B Note until the New Maturity Date, except in the
case of an “Event of Default” as permitted under the terms of the Series B Notes. The Company may make payments against the Series B Notes at any time after (i) the results of a 24 week time primary efficacy endpoint of the
Phase II clinical trial in the United States related to the Company’s Hair Stimulating Complex product has been delivered to the Company’s Board of Directors (the “Board”), and (ii) the New Maturity Date, if
the holder(s) of such Series B Notes have not elected to convert such Series B Notes or there has not been a Series B Conversion (as defined below) before the New Maturity Date. Prior to making each and any such payment, the Company shall provide
the holder of such Series B Note with thirty (30) days prior written notice during which period the such holder may elect to convert any or all of such Series B Note to equity. Only the holder of Series B Note(s) with rights to a majority of
the aggregate outstanding balances of the Series B Notes may exercise any rights under the Security Agreements, provided such holder or holders may do so on behalf of all holders. 

4.2 Conversion of the Series B Notes. All principal amounts outstanding under the Series B Notes will convert automatically and without
further action by the Parties into shares of the Series B Preferred of the Company in accordance with Section 3 of each Series B Note as if the holder had demanded conversion of such Series B Note (which demand will have been deemed to occur)
upon both (i) the achievement of the Trigger Amount, and (ii) the delivery by the Company of written notice of such achievement to Lordship Holdings, which notice shall identify each payment or transaction and the proceeds thereof, that
caused the Trigger Amount to be achieved (a “Series B Conversion”). 
 4.3 Conversion of Assigned Series B
Notes. Upon a Series B Conversion (and only upon a Series B Conversion), all principal amounts outstanding under the Series B Notes that are no longer held by Lordship Holdings will convert automatically and without further action by the Parties
into shares of the Series B Preferred of the Company in accordance with Section 3 of each Series B Note as if the holder had demanded conversion of such Series B Note (which demand will have been deemed to occur). 

4.4 Release of Security Interests. The Parties hereby agree that upon either: (a) a Series B Conversion; or (b) the election
by the holders of Series B Note(s) with rights to a majority of the aggregate outstanding balances of the Series B Notes to convert such Series B Notes and their subsequent conversion; all security interests under the Security Agreements shall be
immediately released and discharged, and all interest in and to all tangible and intangible assets under the Security Agreements shall be returned, re-assigned and released in full to the Company, including,
all Intellectual Property Rights 

  
 -4- 

 
(the “IP Assets”). The Lordship Group shall, at the expense of the Company, take all requisite action to effect the foregoing discharge of security interests and
termination of the Security Agreements, including, (i) making all requisite filings, at the Company’s expense, including filing UCC-3 termination statements, and filing notices with the United States
Patent and Trademark Office or any other Governmental Body; and (ii) instructing all agents and third parties to effect the foregoing release and discharge of the foregoing security interests. 

4.5 DELETED. 
 4.6 Deemed
Liquidation. If the Company intends to consummate a Deemed Liquidation before or after the New Maturity Date, and some or all of principal amounts under the Series B Notes remain outstanding, then Lordship Holdings may elect to convert such
principal amounts under the Series B Notes before the consummation of such Deemed Liquidation transaction into shares of Series B Preferred by written notice delivered to the Company in accordance with the terms and conditions of such Series B Notes
(as amended by this Agreement). To the extent that Lordship Holdings does not convert all such principal amounts at least fifteen (15) days before the consummation of the Deemed Liquidation, the Company or any other Person may pay all or a
portion of the balances remaining under the Series B Notes notwithstanding that such payment would occur before the New Maturity Date. The Series B Notes may not be converted after the consummation of the Deemed Liquidation. 

4.7 Amendments to the Notes. Section 4 of each Series B Note is amended such that it shall refer to Section 5.5 of the Charter
(rather than “Section 5.7”). Each Series B Note is amended such that “Charter” shall refer to the Amended and Restated Certificate. Lordship Holdings acknowledges and agrees that the additional shares granted under
Section 7 and the issuance of 190,377 shares of Common Shares granted to Huapont in connection with the Huapont Financing will not be deemed a Securities Issuance Transaction under the Series C Note and therefore an Adjustment with respect to
such additional shares is not required. Each of the 2016 Notes is hereby amended to provide all amounts due thereunder shall be due and payable in one installment on July 25, 2018. The 2016 Note dated February 15, 2016 is hereby amended to
increase the principal amount by $34,182. Section 6 of the Series B Notes is amended to read as set forth in Exhibit A. 
 4.8
IP Licenses. Should the holder of the Series B Notes (or any Series B Note, or assignee of any right under the Series B Note) take possession of the IP Assets by exercising rights set forth in the Security Agreements, such party (or parties)
shall first agree to assume the LSA license currently in advance stages of negotiation with Huapont (however, only if such license is finalized and entered into by the Company), together with all the rights and obligations of the Company under such
license agreement. 
 4.9 Partial Sale of IP. The Company may sell a portion of the IP Assets free and clear of the lien granted in
accordance with the Security Agreements, and Lordship Holdings hereby, as it relates exclusively to the Security Agreements and no other consent rights it might have, gives its irrevocable consent to the Company selling such IP Assets free and clear
of such lien, provided that such portion of the IP Assets constitutes non-essential assets only, and in any case does not include any intellectual property that is used or licensed in connection with the
Company’s Hair Stimulating Complex product or any derivatives thereof, if the proceeds of such sale, together with all prior Trigger Transactions, results in the Trigger Amount being achieved and such sale is completed on or before the New
Maturity Date. 

  
 -5- 

 5. Amended and Restated Financing Documents. Effective as of the Closing, Lordship
Group hereby (i) waives all of its rights under the Previous Stockholder Rights Agreement and any lack of performance by the Company thereunder, (ii) approves and gives its consent to the Huapont Financing, and agrees to enter into each of
the Amended and Restated Investment Documents, at which time the Amended and Restated Investment Documents will constitute the full and entire understanding and agreement between the Parties with respect to the subject matters thereof, and any other
written or oral agreement relating to the subject matter thereof existing between any of the Parties including the Previous Stockholder Rights Agreements will be expressly superseded and of no further effect. 

6. Series B SPA and Product License Term Sheet. To the extent that the Series B SPA or Product License Term Sheet have any obligations,
covenants, representations or warranties that remain unexpired and have not lapsed as of the Effective Time, then, effective at the Effective Time, all obligations, covenants, representations or warranties under the Series B SPA and Product License
Term Sheet will be deemed to have expired or to be terminated, and the Series B SPA and Product License Term Sheet will be deemed terminated and of no further effect. 

7. Participation. 
 7.1
Controller. Promptly after the Closing, the Company will hire an experienced controller (e.g. a financial controller or CFO) or operating officer who will be responsible for the Company’s obligations under this Section 7, and will
use his or her best efforts be available to the members of the Board during each Board meeting required under Section 7.2. Such individual shall be actively involved in reviewing the Company financials and preparing the Company’s budget.
Additionally, the Board shall form a Budget Committee that shall work with such individual and who shall oversee such individual. Any payments to be made by the Company that do not comply with a budget approved by the Board must be approved by such
individual and the Budget Committee. The person hired for this purpose may be replaced by another experienced controller or operating officer by the Board. Until such time that the Company has identified an appropriate individual, the foregoing role
will be filled by a party reasonably acceptable to the parties. 
 7.2 Recurring Board Meetings. The Company will schedule and conduct
regular meetings of the Board at least every two (2) months on the same day of the month (e.g. the second Wednesday of such month) and will not reschedule such meeting unless: (a) that day falls on a federal holiday of the United States of
America, in which case the Company will reschedule it for the same week day of the following week; or (b) it is rescheduled to a date consented to by a Party of the Lordship Group or one of the members of the Board designated by Lordship
Holdings. The Company will circulate an agenda to the members of the Board at least two days before such meetings, together with an updated budget that will be presented to the Board. The Company may schedule other meetings of the Board, provided
that it gives Board members the notice required under Delaware General Corporate Law. 
 7.3 Material Licenses. The Company may not
enter into: (i) any material license of Company patents or material sales agreement for the sale of the Company’s products (not including sales of materials or supplies to other Persons for the manufacture of the Company’s products)
for an amount greater than $100,000; (ii) the sale of debt or equity securities of more than $300,000; and (iii) any transaction that would constitute a Deemed Liquidation (each a “Material Transaction”) without the
approval of at least one of Lordship Holdings, Lordship Ventures, or a Board member designated by Lordship Holdings unless: 
 7.3.1 Lordship
received notice that the Company is pursuing discussions or negotiations regarding a potential Material Transaction with seven (7) business days of the onset of substantive discussions with the counterparty that includes the exchange of a term
sheet or otherwise the exchange of material terms (“Substantive Discussions”); and 

  
 -6- 

 7.3.2 either Lordship Holdings is invited to participate; or the Company informs Lordship
Holdings that a partner from Sheppard Mullin Richter & Hampton LLP (or other law firm that is reasonably acceptable to the Company and Lordship Holdings) is involved in the Substantive Discussions and negotiations, and such partner (or his
or her partner) is and remains involved in the Substantive Discussions and negotiations throughout the course thereof; OR 
 7.3.3
Lordship received notice under 7.3.1, and either the Board or at least one of Lordship Holdings, Lordship Ventures, or a Board member designated by Lordship Holdings approved the material terms of such Material Transaction, and thereafter the
Company shall be free to pitch to, offer to, negotiate with or otherwise engage in discussions with other parties based on the same material terms without further notice to Lordship Holdings; provided that with respect to Substantive Discussions
with such additional parties, either Lordship Holdings is invited to participate; or a partner from Sheppard Mullin Richter & Hampton LLP (or other law firm that is reasonably acceptable to the Company and Lordship Holdings) is involved in
the Substantive Discussions and negotiations, and such partner (or his or her partner) is and remains involved in the Substantive Discussions and negotiations throughout the course thereof. 

Notice may include discussion of the Material Transaction at a Board meeting that would constitute a valid Board meeting under Delaware law. 

7.4 Expiration. This Section 7 will expire upon the earlier of: (a) achievement of the Trigger Amount, (b) a Deemed
Liquidation, or (c) an IPO. 
 8. Additional Shares. In consideration for entering into this Agreement, at the Closing, the
Company will issue to Lordship Holdings 2,600,000 shares of the Company’s Common Shares without any additional payment due. Lordship Holdings hereby makes the same representations and warranties as made by the Investor in Section 5 of the
Series D Stock Purchase Agreement to be executed at the Closing by Huapont, and for such purposes “Investor” shall refer to Lordship Holdings and “Shares” shall refer to the 2,600,000 of Common Stock referred to in this
Section 8. Notwithstanding the foregoing, Lordship Holdings does not make any representation or warranty concerning anything related to the law and regulations of the People’s Republic of China or any of its affiliated regulatory bodies.

 9. Payment. At the closing, the Company will pay to Lordship Holdings $50,000 promptly but in any case within five
(5) business days of the Closing which amount shall apply as payment against the balance of the 2016 Note that is dated April 21, 2016. Such payment shall be made by wire transfer of immediately available funds to the following account:

  

			
	 Bank
	  	Wells Fargo Bank
	 Routing Number
	  	
	 Account Title
	  	
		
	 Account Number
	  	

 10. Termination of Lordship Agreements. Lordship Ventures, Lordship Holdings, and Jackson each
hereby represents and warrants to the Company, and the Company represents and warrants to Lordship Ventures, Lordship Holdings and Jackson, that, to each party’s knowledge: (a) as of the Effective Date there are no agreements,
understandings or arrangements, in writing or otherwise, between the Company, or any party on its behalf, and any Person in the Lordship Group, other than the Lordship Agreements, and (b) as of the Closing, there will be no agreements,
understandings or arrangements, in writing or otherwise, between the Company, or any party on its behalf, and any Person in the Lordship Group, other than the following agreements and instruments (the “Continuing
Agreements”): the Amended and Restated 

  
 -7- 

 
Financing Documents, this Agreement, the Series B Notes (as amended by this Agreement), the provisions of the Series C Note obligating the Company to effectuate an Adjustment upon the completion
of any Securities Issuance Transaction (as defined in the Series C Note), the Security Agreements, the 2016 Notes, the Success Fee Agreement, the Release, the Indemnification Agreement, the Distribution and Contribution Agreement, the Series D
Warrants and the following Sections of the Third NPA: 6.1(c)-(g),(j),(k), Article VIII and all definitions in such agreement, provided that they will not be in effect from the Effective Date to six (6) months thereafter. Except for the
Continuing Agreements, effective as of the Effective Time, each of the Lordship Agreements, and all rights, covenants and obligations therein, shall be terminated in their entirety, rendered null and void and of no force and effect. The sole and
exclusive remedy for any breach of the foregoing representation or warranty in this Section 10 is that the Parties agree that any agreements, understandings or arrangements, in writing or otherwise, between the Company, or any party on its
behalf, and any Person in the Lordship Group, other than those specified in Section 10(b) above are hereby terminated and nullified. 

11. Release of Claims.  

11.1.1 Lordship Group Primary Release. In consideration for entering into this Agreement and other consideration that each Lordship
Party hereby acknowledges as sufficient, Lordship Ventures, Lordship Holdings and Jackson, on its own behalf and on behalf of each of his or its Affiliates, and each of its respective officers, directors, members, managers, partners,
representatives, agents, heirs, family members, executors, agents, and assigns (collectively, “Lordship Releasors”), hereby and forever irrevocably releases the Released Parties from, and agrees not to sue
concerning, or in any manner to institute, prosecute, or pursue, any Claim, complaint, charge, duty, obligation, demand, or cause of action relating to any matters of any kind, and waives and discharges each of the foregoing, whether presently known
or unknown, suspected or unsuspected, accrued or unaccrued, contingent or otherwise, that any of the Lordship Releasors may possess against any Released Party arising from any omissions, acts, facts, damages or Losses, that have occurred up until,
and including, the Closing, including, as pertaining to any Lordship Agreement, the Previous Stockholder Rights, any Lordship Protective Right or the Huapont Financing, provided however, that nothing in this Section 11.1.1 applies, in any way
to anything related to the Lordship Releasor’s rights under or with respect to the Continuing Agreements. Each Person in the Lordship Group represents and warrants that, as of the Effective Time, such Person has made no assignment or transfer
of any right, claim, complaint, charge, duty, obligation, demand, cause of action, or other matter waived or released by this Section 11.1.1. 

11.1.2 Lordship Group Specific Release. In consideration for entering into this Agreement and other consideration that each Lordship
Party hereby acknowledges as sufficient, Lordship Releasors, hereby and forever irrevocably releases the Released Parties from, and agrees not to sue concerning, or in any manner to institute, prosecute, or pursue, any Claim, complaint, charge,
duty, obligation, demand, or cause of action, and waives and discharges each of the foregoing, whether presently known or unknown, suspected or unsuspected, accrued or unaccrued, contingent or otherwise, that any of the Lordship Releasors may
possess against any Released Party arising from any breach by the Company of its representations, warranties, covenants or other obligations under the Continuing Agreements that have occurred any time up until, and including, the Closing. Each
Person in the Lordship Group represents and warrants that, as of the Effective Time, such Person has made no assignment or transfer of any right, claim, complaint, charge, duty, obligation, demand, cause of action, or other matter waived or released
by this Section 11. 
 11.1.3 Lordship Group Additional Waiver. In particular and without limitation to the foregoing releases in
Sections 11.1.1 and 11.1.2, the Lordship Releasors: (a) waive all breaches and under the Convertible Note Documents; and (b) acknowledge and agree that none of the Huapont Financing, the Closing, nor any event, action, or failure to act
before the Closing shall be treated as an “Event of 

  
 -8- 

 
Default” or breach under the Series C Note, Series B Notes, the surviving provisions of the Third NPA, or Security Agreements. For the avoidance of doubt, none of the interest accrued under
the Series B Notes or 2016 Notes will be released but will be calculated instead at the interest rate applicable if no breach or “Event or Default” has occurred through until the Closing. 

11.2 Company. In consideration for entering into this Agreement and other consideration that the Company hereby acknowledges as
sufficient, the Company on its own behalf and on behalf of each of his or its Affiliates, and each of its respective officers, directors, members, managers, partners, representatives, agents, heirs, family members, executors, agents, and assigns
(collectively, “Company Releasors”), hereby and forever irrevocably releases Lordship Ventures, Lordship Holdings and Jackson and each of their respective Affiliates, and each of their respective current and former officers,
directors, employees, agents, investors, attorneys, members, shareholders, administrators, insurers, representatives, trustees, divisions, and subsidiaries, and predecessor and successor Persons and assigns (collectively, the “Lordship
Released Parties”) from, and agrees not to sue concerning, or in any manner to institute, prosecute, or pursue, any Claim, complaint, charge, duty, obligation, demand, or cause of action relating to any matters of any kind, and waives
and discharges each of the foregoing, whether presently known or unknown, suspected or unsuspected, accrued or unaccrued, contingent or otherwise, that Company Releasors may possess against any Lordship Released Party arising from any omissions,
acts, facts, damages or Losses, that have occurred up until, and including, the Closing, including, as pertaining to any Lordship Agreement, any Lordship Protective Right or the Huapont Financing. The Company represents and warrants that, as of the
Effective Time, the Company has made no assignment or transfer of any right, claim, complaint, charge, duty, obligation, demand, cause of action, or other matter waived or released by this Section 11. 

11.3 Scope. To clarify the intent of the Parties, nothing in this Section 11 will be read to waive breaches or defaults after the
Closing by any of the Parties under the Amended and Restated Investment Documents the Continuing Agreements, or any of the other agreements or instruments set forth in Section 10(b), or to release any Claims or Losses arising after the Closing.
The release and agreements not to sue under this Section 11 does not extend to the obligations, representations or warranties under this Agreement. 

12. California Civil Code Section 1542. The Company and the Lordship Parties acknowledges that they have been advised
to consult with legal counsel and are familiar with the provisions of California Civil Code Section 1542, a statute that otherwise prohibits the release of unknown claims, which provides as follows: 

A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING
THE RELEASE, WHICH IF KNOWN BY HIM OR HER MUST HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR. 
 The Company and the Lordship Parties,
being aware of said code section, agree that the releases set forth in Section 11 are intended as a full and complete release, and agree to expressly waive any rights they may have thereunder, as well as under any other federal or state statute
or common law principles of similar effect. 
 13. No Pending or Future Lawsuits. The Lordship Parties each represents and warrants
that they have no lawsuits, claims, or actions pending in their name, or on behalf of any other Person or entity, against any Released Party. The Lordship Parties each also represents and warrants that such Party does not intend to bring any claims
on its or his own behalf or on behalf of any Released Party. The Company represents and warrants that it has no lawsuits, claims, or actions pending in its name, or on behalf of any other Person or entity, against any Lordship Released Party. The
Company also represents and warrants that it does not intend to bring any claims on their own behalf or on behalf of any Released Party. 

  
 -9- 

 14. Third Party Beneficiaries. The Released Parties (other than Company) are third
party beneficiaries of this Agreement in accordance with its terms. The Lordship Released Parties (other than the Lordship Parties) are third party beneficiaries of this Agreement in accordance with its terms. 

15. Other Matters. 
 15.1
Replacement Note. 
 15.1.1 Lordship Holdings hereby represents and warrants that (i) it is the Holder of Series B Note 3, (ii)
following a diligent search, it has been unable to locate the original version of Series B Note 3 (though it retains a photocopy thereof), and (iii) Series B note has not been sold, transferred or pledged. 

15.1.2 At the Closing, in accordance with Section 8 of Series B Note 3, the Company shall provide Lordship Holdings with a replacement
originally executed Series B Note 3. 
 15.1.3 The Holder hereby agrees to indemnify and hold the Company harmless for any claim of
ownership to Series B Note 3 as the result of the tendering to the Company of the previously issued (and misplaced) version of such note. 

15.2 Board Designee Indemnification Agreements. At the Effective Time, the Company shall executed and deliver to each of Lordship
Holding’s designees to the Board, the Indemnification Agreements attached hereto as Exhibit B, which the Company represents are in substantially the same form as the Indemnification Agreement being provided to Huapont’s Board
designee at the Closing. If Lordship Holding’s designees to the Board shall change, the Company shall provide an Indemnification Agreement, in the substantially the same form, to any new designee at the time that such new designee is added to
the Board. 
 16. Miscellaneous. 

16.1 Successors and Assigns. Lordship Holdings and any subsequent holder of the Series C Note or Series B Notes shall only be assigned
or otherwise receive such convertible note (or rights thereunder) subject to the terms and conditions of this Agreement, and must first agree with the Company in writing to comply with the terms and conditions set forth in this Agreement that apply
to or affect the Series C Note or Series B Notes (as applicable) or govern the rights of the holder of such convertible notes or the rights or obligations of the Company under such convertible notes. The terms and conditions of this Agreement shall
inure to the benefit of and be binding upon the respective successors and assigns of the Parties. Nothing in this Agreement, express or implied, is intended to confer upon any Person other than the Parties or their respective successors and assigns
any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement. 

16.2 Governing Law. This Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, without
regard to conflict of law principles that would result in the application of any law other than the law of the State of Delaware. 

  
 -10- 

 16.3 Counterparts. This Agreement may be executed in two (2) or more
counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including .pdf) or other transmission method and any
counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. 
 16.4
Titles and Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement. 

16.5 Notices. All written notices hereunder by any Party shall be given by personal delivery (including reputable courier service), fees
prepaid, or by sending such notice by registered or certified mail return receipt requested, postage prepaid or via an internationally recognized overnight courier service. Such notices shall be deemed to have been given, delivered and received upon
receipt or attempted delivery (if receipt is refused), as the case may be, and the date of delivery identified by the applicable postal service on any return receipt card or confirmation by courier service, even if such delivery was refused. Notices
also may be sent by facsimile transmission or email, which shall be deemed given, delivered and received when sent if: (a) the Party transmitting the notice also sends such notice the same day by any of the other notice methods described above;
or (b) the receiving Party confirms receipt in any manner. Each such notice must name the individual and title designated for notices and be addressed to the Party as set forth on the signature pages below. Any Party, by five (5) days
written notice to the other as above described, may alter the address or named recipient for receipt by it of written notices hereunder. If notice is given to the Lordship Group, a copy shall also be sent to Satz Law Group LLC, 230 Passaic Avenue, 1st floor, Fairfield, NJ 07004, Attn: Brian M. Satz, Esq., Facsimile: (973) 255-1010, Email: bsatz@satzlawgroup.com; and if notice is given to the Company, a copy
shall also be given to Sheppard, Mullin, Richter & Hampton LLP, 333 S. Hope Street, 48th Floor, Los Angeles, CA 90071, Attn: Will Sarat Chuchawat, Esq., Facsimile: (213) 443-2708, Email: wchuchawat@sheppardmullin.com. 
 16.6 Amendments and Waivers. Any term of this
Agreement may be amended, terminated or waived only with the written consent of the Company and a Person in the Lordship Group. Any amendment, termination or waiver by a Person in the Lordship Group will be binding upon each Person in the Lordship
Group and any assignees. 
 16.7 Further Assurances. Each of the Parties hereto shall, at its expense, and shall cause its respective
Affiliates to, from time to time at the request of the other Party, without any additional consideration, furnish the other Party such further information or assurances, execute and deliver such additional documents, instruments and
conveyances, and take such other actions and do such other things, as may be reasonably necessary, appropriate or desirable, to carry out the provisions of this Agreement and give effect to the transactions contemplated hereby. 

16.8 Delays or Omissions. No delay or omission to exercise any right, power or remedy accruing to any party under this Agreement, upon
any breach or default of any other party under this Agreement, shall impair any such right, power or remedy of such non-breaching or non-defaulting party nor shall it be
construed to be a waiver of any such breach or default, or an acquiescence therein, or of or in any similar breach or default thereafter occurring; nor shall any waiver of any single breach or default be deemed a waiver of any other breach or
default previously or thereafter occurring. Any waiver, permit, consent or approval of any kind or character on the part of any party of any breach or default under this Agreement, or any waiver on the part of any party of any provisions or
conditions of this Agreement, must be in writing and shall be effective only to the extent specifically set forth in such writing. All remedies, either under this Agreement or by law or otherwise afforded to any party, shall be cumulative and not
alternative. 

  
 -11- 

 16.9 Severability. If any provision of this Agreement is held invalid or
unenforceable by an arbitrator in arbitration or by a court of competent jurisdiction, the court or arbitrator should endeavor to give effect to the Parties’ intentions as reflected in such provision, and if the court or arbitrator cannot do
so, then strike the invalid or unenforceable provision in which case this entire Agreement will be construed as if not containing such particular invalid or unenforceable provision and the rights and obligations of the Parties will be construed and
enforced accordingly with the remaining provisions given their full force and effect. 
 16.10 Entire Agreement. This Agreement
(including the Exhibits hereto) constitutes the full and entire understanding and agreement between the Parties with respect to the subject matter hereof, and any other written or oral agreement relating to the subject matter hereof existing between
the Parties is expressly canceled. The terms and conditions of this Agreement amend and modify any conflicting terms and conditions of any Continuing Agreement (or any other agreement between the parties as of the Closing other than the Amended and
Restated Investment Documents). This Agreement includes the following Schedules and Exhibits: 
 Schedule A – Lordship Agreements 

Exhibit A – Amended and Restated Investment Documents 

Exhibit B - Board Member Indemnification Agreements 

16.11 Dispute Resolution. Any dispute, controversy or claim arising from this Agreement other than for injunctive or other equitable
relief, shall be submitted to final, binding and non-appealable arbitration before the American Arbitration Association (the “AAA”). A single neutral arbitrator shall preside unless a
Party requests a panel of three neutral arbitrators, in which case three arbitrators will preside, and the Party that requested a proceeding with three arbitrators will pay 2/3 of the fees of the arbitrators presiding. To the extent the identity of
the arbitrator(s) is not agreed by the Parties within fourteen (14) days following the commencement of notice by any Party of its intention in writing to immediately submit a dispute for arbitration, the AAA will have the discretion to select
the neutral arbitrator that it believes is best suited for the arbitration in terms of experience and availability, having reasonable experience in corporate finance transactions of the type provided for in this Agreement, and its selection will be
final. Such arbitration shall take place in Los Angeles, California, and shall be conducted in accordance with the commercial rules of the AAA then in effect. Any matters (such as petitions for injunctions or other equitable relief) not otherwise
covered by the aforementioned arbitration by the AAA shall be resolved exclusively in the state and federal courts located in the City of Los Angeles, California, and each Party irrevocably and unconditionally (a) submits to the exclusive
jurisdiction and venue of the United States District Court for the Central District of California, or any state court sitting in Los Angeles County, California, for the purpose of any suit, action or other proceeding arising out of or based upon
this Agreement, (b) hereby waives, and agrees not to assert any claim that it is not subject personally to the jurisdiction of the above-named courts, that the suit, action or proceeding is brought in an inconvenient forum, that the venue of
the suit, action or proceeding is improper or that this Agreement or the subject matter hereof may not be enforced in or by such court. 

16.12 Interpretation. This Agreement does not create a partnership, franchise, joint venture, agency, fiduciary or employment
relationship between the Parties. The word “or” as used in this Agreement has the meaning equivalent to “and/or”. The terms ‘include’ and ‘including’ will be deemed to be immediately followed by the phrase
“without limitation”. This Agreement does not confer any rights or benefits to any third party beneficiaries except for as stated in Section 11. The headings appearing at the beginning of sections have been inserted for identification
and reference purposes only and must not be used to construe or interpret this Agreement. The word “will” expresses an obligation of a party 

  
 -12- 

 
equivalent to “shall” when a party is the subject of the sentence. The Agreement will not be construed in favor of or against any party by reason of the extent to which any party
participated in the preparation of this Agreement. The headings appearing at the beginning of several Sections contained in this Agreement have been inserted for identification and reference purposes only and must not be used to construe or
interpret this Agreement. Should any terms of this Agreement be determined to be otherwise void or unenforceable by any arbitrator or court of competent jurisdiction, such terms will be deemed amended to achieve as nearly as possible the same
economic effect as the original terms and the remainder of this Agreement will remain in full force and effect. The parties hereto confirm that they have requested that this Agreement and all attachments and related documents be drafted in English.

 [Signature Page Follows] 

  
 -13- 

 IN WITNESS WHEREOF, the Parties have executed this Conversion, Termination and Release
Agreement as of the Effective Date. 
  

							
	LORDSHIP VENTURES LLC	 		 		 	
	c/o Lordship A.S.	 		 		 	
				
		 		 		 	HISTOGEN, INC.
	Attention: Jonathan Jackson	 		 		 	10655 Sorrento Valley Road
	Facsimile:	 		 		 	San Diego, CA 92121
	Email:	 		 		 	Attention: President
		 		 		 	Facsimile:
		 		 		 	Email:
				
	 /s/ Jonathan Jackson
	 		 		 	
	By Jonathan Jackson, Managing Member	 		 		 	
				
	LORDSHIP VENTURES HISTOGEN	 		 		 	
	HOLDINGS LLC	 		 		 	 /s/ Dr. Gail Naughton

	c/o Lordship A.S.	 		 		 	By Dr. Gail Naughton, President and CEO

  

	
	Attention: Jonathan Jackson
	Facsimile:
	Email:
	
	 /s/ Jonathan Jackson

	By Jonathan Jackson, Managing Member
	
	JONATHAN JACKSON
	c/o Lordship A.S.
	
	Attention: Jonathan Jackson
	Facsimile:
	Email:
	
	 /s/ Jonathan Jackson

	By Jonathan Jackson

 [Signature Page to Conversion, Termination and Release Agreement] 

 Schedule A 

Lordship Agreements 
 I. Convertible
Notes and Related Agreements 
  

					
	 Document
	  	 Dated
	  	 Defined Term

	 1.  Note Purchase Agreement by and between Jackson and the Company
	  	May 5, 2010, as amended on June 30, 2010	  	First NPA
			
	 2.  Note Purchase Agreement by and between Lordship Ventures and the Company,
	  	August 18, 2010, as amended on May 2, 2011	  	Second NPA
			
	 3.  Series B Senior Secured Convertible Notes issued to Lordship Ventures
	  	May 16, 2012, May 30, 2012, June 11, 2012, June 27, 2012, July 11, 2012, July 25, 2012, August 8, 2012, August 9, 2012, August 22, 2012, September 7, 2012, September 21, 2012,
October 5, 2012, October 10, 2012, October 18, 2012, October 30, 2012, and November 2, 2012	  	Preliminary B Notes
			
	 4.  Confirmation of Terms re: Contemplated Convertible Loan
	  	September 22, 2011, December 7, 2011, December 28, 2011, December 29, 2011, January 4, 2012, January 12, 2012, January 18, 2012, January 24, 2012, February 22, 2012, March 22, 2012,
May 2, 2012, and April 6, 2012,	  	Loan Term Sheets
			
	 5.  Series A Senior Secured Convertible Notes, issued by the Company to Lordship
Ventures, in an aggregate amount of $3,000,000.
	  	May 5, 2010, June 22, 2010 and August 18, 2010,	  	Series A Notes
			
	 6.  Note Purchase Agreement by and between Lordship Holdings and the Company
	  	November 19, 2012	  	Third NPA
			
	 7.  Senior Secured Convertible Note Convertible into Shares of Series B Preferred
Stock No. 1 for $2,212,500
	  	November 19, 2012	  	Series B Note 1
			
	 8.  Senior Secured Convertible Note Convertible into Shares of Series B Preferred
Stock No. 2 for $179,500
	  	November 19, 2012	  	Series B Note 2

  
 [Schedule A] 

					
	 9.  Senior Secured Convertible Note Convertible into Shares of Series B Preferred
Stock No. 3 for $200,000
	  	December 11, 2012	  	Series B Note 3 (and together with the Series B Note 1 and Series B Note 2, the “Series B Notes”)
			
	 10.  Series C Convertible Note issued by the Company to Lordship Holdings in the
original principal amount of $3,000,000, as set forth in the Third NPA (replacing all predecessor notes aggregated in the Series C Note)
	  	November 19, 2012	  	Series C Note (and together with the First NPA, Second NPA, Third NPA, Loan Term Sheets, Series A Notes, Preliminary Series B Notes, Series B Notes, the “Convertible Note
Documents”)
			
	 11.  Security Agreement by and between Lordship Holdings and the Company, as amended
on January 1, 2014
	  	November 19, 2012	  	Security Agreement (and together with the Patent Security Agreement, the Trademark Security Agreement, and the Copyright Security Agreement, the “Security Agreements”)
			
	 12.  Patent Security Agreement by and between Lordship Holdings and the
Company
	  	November 19, 2012	  	Patent Security Agreement
			
	 13.  Trademark Security Agreement by and between Lordship Holdings and the
Company
	  	November 19, 2012	  	Trademark Security Agreement
			
	 14.  Copyright Security Agreement by and between Lordship Holdings and the
Company
	  	November 19, 2012	  	Copyright Security Agreement
			
	 15.  Promissory Notes issued by the Company to Lordship Holdings in an aggregate
amount of $100,000
	  	February 15, 2016, March 20, 2016, and April 21, 2016	  	2016 Notes

 II. Previous Stockholder Rights Agreements 
  

					
	 Document
	  	 Dated
	  	 Defined Term

	 16.  Right of First Refusal and Co-Sale
Agreement, by and among Lordship Holdings, the Company and certain stockholders of the Company
	  	November 19, 2012	  	ROFR Agreement
		  		  	
	 17.  Voting Agreement by and among Lordship Holdings, the Company and certain
stockholders of the Company
	  	November 19, 2012	  	Voting Agreement
		  		  	
	 18.  Investor Rights Agreement by and between Lordship Holdings and the
Company
	  	November 19, 2012	  	IRA (and together with the ROFR Agreement and Voting Agreement, the “Previous Stockholder Rights Agreements”)

  
 [Schedule A] 

 III. Other Agreements 
  

					
	 Document
	  	 Dated
	  	 Defined Term

	 19.  Strategic Relationship Success Fee Agreement, by and between Lordship Ventures
and the Company, as amended on August __, 2016
	  	November 19, 2012	  	Success Fee Agreement
			
	 20.  Stock Purchase Agreement by and between Lordship Holdings and the
Company
	  	November 19, 2012	  	Series B SPA
			
	 21.  Term Sheet for License Agreement by and between Lordship Holdings and the
Company
	  	November 19, 2012	  	Product License Term Sheet
			
	 22.  Common Stock Warrant to purchase 2,000,000 shares of Common Stock
	  	November 19, 2012	  	Common Stock Warrant
			
	 23.  Release executed by Lordship Ventures and the Company
	  	October 5, 2012	  	Release
			
	 24.  Indemnification Agreement by and between Lordship Ventures and the
Company
	  	January 12, 2012	  	Indemnification Agreement
			
	 25.  Warrants to purchase 100,000 shares of Series D Preferred Stock, pursuant to a
Series D Convertible Preferred Stock Warrants issued by the Company to Lordship Holdings 

	  	February 15, 2016, March 20, 2016 and April 21, 2016	  	Series D Warrants
			
	 26.  Loan Agreement by and between Lordship Holdings and the Company
	  	November 20, 2015	  	Loan Agreement
			
	 27.  Distribution and Contribution Agreement by and among the Parties
	  	November 19, 2012	  	Distribution and Contribution Agreement

  
 [Schedule A] 

 Exhibit A 

“Section 6. The occurrence of any of the following events shall be deemed to constitute an “Event of Default”
hereunder: (a) the failure of the Company to pay the principal amount of this Note or any of the other Notes issued pursuant to the Purchase Agreement, together with all accrued but unpaid interest, on or after the Payment Date upon demand of
the Holder thereof; (b) immediately upon the failure of the Company to perform any covenant or agreement in any material respect set forth in this Note, any of the other Notes or any of the other Transaction Documents, unless such failure could
be remedied, in which case only if such failure shall continue unremedied for a period of thirty (30) days after written notice of such failure is delivered to the Company; (c) the entry of a judgment, order or decree against the Company
with respect to, any encumbrance against, the making of any levy, seizure or attachment of, or the occurrence of any action which results in the forfeiture of the Collateral; (d) unless the security interest granted under the Security Agreement
shall be released in accordance with the terms of the Security Agreement, the Company takes action that it does not have the lawful right to take causing the security interest and lien of the Holder on any portion of the Collateral to not be in full
force and effect as a fully perfected first lien, or Company improperly and without lawful right contests the validity, enforceability, or perfection of any lien granted pursuant to the Transaction Documents with respect to any material items of
Collateral, or the Company shall seek to disaffirm, terminate, limit or reduce its obligations under any of the Transaction Documents, and (e) any Liquidation Event. As used herein, “Liquidation Event” means the
occurrence or institution by or against the Company or any of its Subsidiaries of (i) any bankruptcy, reorganization, receivership or insolvency proceeding, (ii) any appointment of a receiver or custodian for all or a substantial portion
of the Company’s property; (iii) any assignment for the benefit of, or composition or arrangement with, the creditors of the Company (whether or not pursuant to bankruptcy or other insolvency laws), or (iv) any dissolution,
liquidation, or other marshalling of the assets and liabilities of the Company. 
 For purposes hereof, the term “Transaction Document” shall mean
(i) the Conversion, Termination and Release Agreement by and among the Holder and the Company, among others, dated August___, 2016 and (ii) those agreements and instruments that were Transaction Documents prior to the Effective Date and
that are also Continuing Agreements, not including the Success Fee Agreement. 
 For purposes hereof, the term “other Notes” shall mean those
agreements and instruments that were Notes prior to the Effective Date and that are also Continuing Agreements, not including the Series B Note. 

  
 [Exhibit A]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00304-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00304-of-00352.parquet"}]]